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“Is it not a strange fate that we should suffer so much  
fear and doubt for so small a thing? 
So small a thing!” 
Boromir, 
The Lord of the Rings – The Fellowship of the Ring, 
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The high antimicrobial consumption in veterinary medicine has become an issue of great 
public concern. Reports on the increase of multidrug-resistant bacteria in animals, humans and 
the environment result in discussions of the antimicrobial treatment in veterinary medicine. 
After the 16th amendment of the German veterinary medicine act came into force in July 2014, 
a further reduction of antimicrobial consumption was noted in veterinary medicine [1, 2]. As a 
result of improved education and antibiotic stewardship measures for veterinarians and 
farmers, the sales figures of antimicrobial agents in veterinary medicine in Germany decreased 
from 1,706 t in 2011 to 733 t in 2017. This corresponds to a decrease by 57.03 % [2]. However, 
these sales figures cannot be attributed to specific animal species since the majority of 
veterinary antimicrobial agents is approved for use in various animal species. Thus, it is 
unknown how which amounts of which antimicrobial agents are used in Germany for the 
treatment of specific animals or specific diseases in a given animals species. Moreover, it is 
also not known whether there are regional differences in the preferential use of certain 
antimicrobial agents in veterinary medicine. Despite this significant decrease of sales figures 
for antimicrobial agents in veterinary medicine, the German National Resistance Monitoring 
program GERM-Vet, conducted by the Federal Office of Consumer Protection and Food Safety 
(BVL), still identifies a considerable proportion of resistant bacteria from food-producing as well 
as from companion animals [3-6]. The analysis of trends in antimicrobial resistance must be 
conducted with extreme caution, as ‘resistance’ commonly refers to a specific antimicrobial 
agent and a specific bacterial pathogen in a specific disease condition of a given animal 
species. Thus, resistance to pirlimycin among Staphylococcus aureus from mastitis in dairy 
cows differs completely from resistance to ampicillin among Escherichia coli from intestinal 
infections of pigs. Nevertheless, bacteria which exhibit resistance to antimicrobial agents are 
still a major problem and require adequate control measures. 
This project was based on the monitoring of 30 porcine farrow-to-finish farms for their 
frequency of respiratory tract therapies with antimicrobial agents within a one-year period, the 





1.1 Structure of German pig farms 
The German pig industry follows a 
hierarchal system, as represented in Figure 1. The 
purebred pigs of the nucleus farms, on the top of 
the hierarchal pyramid, produce pigs for the 
multiplier farms. In multiplier farms, gilts are 
reproduced and sold to farrow-to-nursery farms. In 
farrow-to-nursery farms, these gilts, later 
designated as sows, reproduce piglets that 
become fattening pigs [7]. The last three levels of 
pig farming (farrow-to-nursery, nursery-to-finish 
and finish farms) can be combined in a farrow-to-
finish farm (closed system) or remain as independent farms. The advantage of the closed farm 
system is a decreased import of pigs that may bring along a variety of porcine pathogens from 
their origins. In closed farms, no piglets from external farms are purchased. Besides, gilts may 
be bred within closed farms to replace older sows. Nevertheless, new gilts of farrow-to-nursery 
or farrow-to-finish farms can also be purchased from external sources of multiplier farms [7, 
8]. Whenever animals are purchased from other farms, they may bring along their farm-specific 
spectrum of bacteria to which these pigs are usually well-adapted. However, when mingled 
with animals in the new farm, a transfer of bacteria between pigs from both farms will occur 
and may result in respiratory or enteric diseases. These diseases are supported by stress 
factors, such as transport, change of the diet in the new farm or fights for social ranking. The 
disadvantage of closed farms is a fast spread of pathogens through all production stages, since 
the separation within those is supposed to be less restrictive [7]. 
Pig farms are organized according to the “all-in, all-out” policy. “All-in, all-out” means that 
a group of pigs is moved as an entire group into a new barn, which was cleaned and disinfected 
before. In this new barn, the next production period starts. Farrow-to-finish farms consist of 
different barns that harbor pigs in their different production stages. Sows are moved through 
different barns while changing between the breeding, gestation and farrowing period (Figure 
2). They are inseminated during the breeding period in a specific barn. The whole group of 
sows is moved into the gestation barn after positive pregnancy test, for approximately 115 
days. In their gestation period, sows are kept in groups within the barn, where they stay in 
close contact. Next, the sows are moved again into the farrowing pen just before giving birth. 
There, the sows deliver a litter of piglets with whom they spend the time of lactation together. 
After the lactation time of 21 or 28 days, the breeding period of the sows starts again. Then, 
the piglets are separated from the sows and moved into the nursery barn. Before starting the 




nursery and fattening periods, piglets with similar weights are rearranged together into boxes. 
This method is used to reach better results in weight gain. At this time, the piglets have a 
weight of approximately 7 kg and are designated as weaners. The growing and finishing period 
starts after the end of the nursery period, when the weaners reach a weight of approximately 
28 kg [7, 8]. Fattening pigs are slaughtered at a weight of 120 kg after a life cycle of 190 to 200 
days [8, 9]. Pig farms are structured on the basis of the black-and-white principle. The black 
area describes the polluted, pathogen-containing outer part of a pig farm. In contrast, the white 
area is defined as the inner part of the pig farm. Before farm workers or veterinarians enter pig 
stables, they have to shower and change their clothes and rubber boots [8]. In farms with a 
high hygienic standard, farm workers change their clothes even before entering a new barn 
with a different pig group. In general, the contact between humans and pigs is minimized as 
much as possible to reduce pathogen transfer [8]. 
 
Pathogens can be transferred directly or indirectly. Direct transmission describes fecal-
oral, airborne, cutaneous, prenatal or perinatal contacts between animals that result in 
pathogen transfer [10]. Indirect transmission occurs when pathogens are attached to objects 
that come into contact with animals. This might be through food, water, soil, dust, inanimate 
objects like buckets or rubber boots, arthropods or rodents which serve as vectors. Moreover, 
humans who come into contact with pigs can also transfer pathogens [10]. 
Good hygienic conditions in intense pig farming and vaccination programs are the first 
lines of defense to avoid respiratory tract infections. Infections in livestock populations, 
especially in pig and poultry farms, are commonly treated as group medications via feed or 
drinking water [11]. In this doctoral thesis, the term pathogen is used to describe disease-
causing bacteria, even though viruses, parasites, yeasts and fungi can also act as causative 
agents of diseases. 
Figure 2 Schematic structure of a closed farm (farrow-to-finish farm), indicating the way of the sows 
with blue and the way of the piglets with green arrows. Black-and-white areas (B/W) are shown as 




In order to characterize the relatedness of selected pathogens in this study, we used 
whole genome sequencing, pulsed-field gel electrophoresis (PFGE) and polymerase chain 
reaction (PCR) methods. The PFGE DNA fragment patterns allow conclusions about the 
genetic relatedness of different isolates, especially during disease outbreaks, based on their 
genomic structure. Isolates that show an indistinguishable DNA fragment pattern are supposed 
to be members of the same clone [12]. Clones are defined as  ҅bacterial cultures isolated 
independently from different sources, in different locations, and perhaps at different times, but 
showing many identical phenotypic and genetic traits that the most likely explanation for this 
identity is a common origin ҆ [13]. Antimicrobial susceptibility testing of bacterial pathogens 
provides helpful information on the basis of which the veterinarian can choose the most 
suitable antimicrobial for therapeutic interventions. In Germany, β-lactams, tetracyclines, 
fluoroquinolones, macrolides, aminoglycosides, sulfonamides and phenicols are approved 
antimicrobial classes of therapeutic interventions of pigs suffering from respiratory tract 
infections [14]. In practice, amoxicillin is the most frequently prescribed antimicrobial agent for 
respiratory tract infections in weaner pigs, followed by tetracyclines and sulfonamides [15]. 
 
1.2 Respiratory tract pathogens 
Respiratory tract infections in pigs are multifactorial diseases, commonly induced by 
viruses, and only in rare cases by bacteria. Bacteria might appear as secondary invaders after 
the damaging of the respiratory tissue. Major viral respiratory tract pathogens in pigs are swine 
influenza virus, porcine reproductive and respiratory syndrome virus (PRRSV) and porcine 
circovirus type 2 (PCV2). Mycoplasma hyopneumoniae, Actinobacillus pleuropneumoniae, 
toxin-producing Pasteurella multocida and Bordetella bronchiseptica are listed as primary 
infectious bacterial pathogens [14]. In contrast, non-toxin producing P. multocida, 
Streptococcus suis and Haemophilus parasuis are considered to be secondary pathogens [14]. 
 
1.2.1 General characteristics of Streptococcus suis 
S. suis isolates are Gram-positive coccoid bacteria, belonging to the order 
Lactobacillales and the family Streptococcaceae. Streptococci are categorized according to 
their type of hemolysis, their colony size and some of them, especially the pyogenic group, are 
classified into Lancefield groups due to their C-polysaccharides [16, 17]. Streptococci are 
grouped into β-hemolytic and non-β-hemolytic streptococci, both including a wide variety of 
mammalian and avian pathogens and are known to have zoonotic potential. The group of β-




pyogenes, Streptococcus agalactiae, Streptococcus dysgalactiae, Streptococcus equi subsp. 
equi, Streptococcus equi subsp. zooepidemicus and Streptococcus canis. Whereas the non-
β-hemolytic streptococci include S. suis, Streptococcus pneumoniae and the viridans group of 
streptococci. Streptococci of the non-β-hemolytic group are considered to be α- or γ-hemolytic 
and are designated as the non-pyogenic group, although not all species belonging to this 
classification accomplish these characteristics [16]. S. suis was formerly classified into 35 
serotypes according to its capsular polysaccharide antigens [18, 19]. However, recent 
examinations of 16S rRNA sequence similarities reclassified S. suis into just 29 serotypes [20, 
21]. For a closer differentiation and typing of virulent and avirulent S. suis isolates, King et al. 
(2002) established a multi-locus sequence typing (MLST) scheme consisting of seven 
housekeeping genes, which revealed a phylogenetically diverse species. S. suis is usually a 
commensal, that is transferred by direct oral or nasal contact as well as by indirect contact and 
colonizes the mucosa of the upper respiratory tract, especially the tonsils, in pigs [19, 23, 24]. 
Infections are caused by virulent serotypes. S. suis serotype 2, followed by serotypes 1, 1/2, 
7 and 9 are designated as the most virulent ones, since they were confirmed in many porcine 
infections in Europe [25]. However, the virulence factors of S. suis are crucial for host 
infection. The streptococcal capsule mediates protection against phagocytosis [26]. The 
hyaluronidase supports the bacterial dissemination within the host [27]. Muramidase-released 
protein, extracellular factor and their weight variants, which are indicated to be heavier or 
lighter than the original proteins due to changes in their amino acid sequence, are considered 
to be associated with virulence [25, 28-31]. Some S. suis isolates express suilysin, which is a 
hemolytic toxin that damages the hosts’ erythrocyte membrane and thereby leading to the 
release of their intracellular substances, like iron, which are necessary for the pathogens’ 
survival [32, 33]. Infections with virulent S. suis can result in meningitis, pneumonia, arthritis, 
septicemia, endocarditis, polyserositis or abortion in pigs [19]. Infections in humans are 
described in people working or living in close contact to pigs, especially on the Asian continent 
in slaughterhouses, pig farms or laboratories. However, S. suis is also detected in other 
mammals, including dogs, cats, ruminants and horses, as well as in birds [19, 34-37]. 
 
1.2.2 Important antimicrobial resistance properties of S. suis 
Resistance to β-lactams in general can be either mediated by (1) β-lactamases, (2) 
changes in the penicillin-binding proteins (PBPs) or (3) reduction of the intracellular 
antimicrobial concentration [38]. However, so far no acquired resistance genes like β-
lactamases or alternate PBPs, such as mecA in S. aureus, have been detected in S. suis [39, 




has been described only for Gram-negative bacteria [41]. Consequently, alterations of single 
amino acids in the penicillin-binding proteins (PBPs) are discussed to have effects on β-lactam 
resistance in S. suis [42, 43]. PBPs are important proteins for the synthesis of the Gram-
positive peptidoglycan cell wall. They are membrane-bound enzymes consisting of three parts, 
a domain at the outer surface, a transmembrane anchor and a cytoplasmatic tail. PBPs are 
classified into proteins with high molecular mass (HMM) and low molecular mass (LMM). The 
HMM PBPs are divided into bifunctional class A proteins that exhibit glycosyltransferase as 
well as transpeptidase functions and monofunctional class B proteins with only transpeptidase 
activity. LMM proteins include class C PBPs with DD-carboxypeptidase function, which, 
however, are supposed to have no effect in β-lactam resistance [41, 44]. Different bacterial 
species have variable numbers of PBPs [45]. Based on the lack of information about PBPs of 
S. suis, the names of the five PBPs (PBP1a, 2a, 1b, 2x and 2b) as well as their conserved 
motifs were adopted from S. pneumoniae [39, 42, 45-47]. Six PBPs are known to occur in 
S.  pneumoniae. Class A summarizes three proteins, named PBP1a, PBP2a and PBP1b. The 
class B proteins in S. pneumoniae are PBP2x and PBP2b, while PBP3 is a class C protein 
[45]. Ser-X-X-Lys, Ser-X-Asn and Lys-Thr/Ser-Gly represent the conserved motifs at the 
catalytic site of the PBPs [43, 46, 48]. β-Lactams bind covalently at the catalytic Ser of the Ser-
X-X-Lys motif and cause an inhibition of the peptidoglycan synthesis with a bactericidal effect 
on growing bacteria [46]. The (a) development of mosaic genes or (b) accumulation of point 
mutations that may cause amino acid alterations in indigenous PBPs can result in a reduced 
affinity to β-lactams. (a) Mosaic genes are composed of various domains: these domains can 
be part of individual genes. During homologous recombination events, closely related species 
may exchange sequences coding for protein domains. These recombinations can result in the 
formation of genes that code for proteins consisting of two indigenous domains and a new 
domain obtained from another species [49]. For example, PBPs of penicillin-resistant 
S.  pneumoniae distinctly differ from those of penicillin-susceptible S. pneumoniae. Different 
parts of the PBPs of a penicillin-resistant S. pneumoniae are similar to regions of PBPs from 
penicillin-resistant S. mitis or S. oralis isolates [50-54]. (b) Point mutations within the genes for 
PBPs may result in amino acid alterations that could have effects on the protein structure. 
Amino acid substitutions nearby or within the active center as well as changes in charge might 
have the greatest effects in mediating β-lactam resistance [47, 55-58]. Furthermore, amino 
acid alterations in PBP2x and PBP2b are associated with low-level β-lactam resistance, 
whereas additional substitutions in PBP1a are considered to confer high-level β-lactam 
resistance in S. pneumoniae [58, 59]. 
Many S. suis isolates are resistant to tetracyclines through acquired resistance genes. 




tetracycline concentration, (2) protection of the ribosomal target site, or (3) enzymatic 
inactivation [60]. Until now, only genes that code for efflux pumps and ribosomal protection 
proteins have been detected in S. suis [61-64]. Tetracyclines bind at the ribosome, inhibit the 
tRNA attachment during translation, and stop the protein biosynthesis. Ribosome protective 
proteins are expressed in the presence of tetracyclines. They bind to the ribosome as well, but 
do not interrupt translation and simultaneously prevent drug binding [60]. Ribosomal protection 
proteins of S. suis are encoded by tet(O), tet(M), tet(W) and tet(O/W/32/O) [43, 63, 64]. Efflux 
pumps transport tetracyclines actively against the concentration gradient out of the cell. 
Thereby, protons provide the necessary energy due to their transfer into the cell along the 
concentration gradient. In S. suis, tet(L), tet(B) and tet(40) were identified to encode such efflux 
pumps [43, 63, 64]. 
S. suis is considered to be mainly susceptible to florfenicol, although florfenicol 
resistance has already been detected in single S. suis isolates [65, 66]. Phenicols inhibit the 
bacterial protein biosynthesis due to binding at the 50S ribosomal subunit [67]. Florfenicol is 
the fluorinated derivate of chloramphenicol and approved to treat food-producing animals. In 
contrast, chloramphenicol is banned from use in food-producing animals [68]. In general, 
resistance to chloramphenicol and/or florfenicol is mediated by a (1) reduction of the 
intracellular phenicol concentration, (2) modification of target sites, or (3) enzymatic 
inactivation [67]. The gene fexA encodes an efflux pump that confers resistance to 
chloramphenicol as well as florfenicol and was detected on the plasmid pStrcfr of S. suis [69, 
70]. On the same plasmid, the gene cfr was located [70]. This gene encodes a RNA 
methyltransferase and mediates resistance to phenicols, lincosamides, oxazolidinones, 
pleuromutilins and streptogramin A [70, 71]. Chloramphenicol acetyltransferase genes (cat) 
are classified into type A or B, which depends on their structure [67]. The chloramphenicol 
acetyltransferase mediates resistance only to chloramphenicol and catA was already identified 
in S. suis [72]. 
Resistance to macrolides and lincosamides is also mediated by a (1) reduction of 
intracellular antimicrobial concentration, (2) modification of ribosomal target sites or (3) 
enzymatic inactivation. Macrolides, lincosamides and streptogramin B agents have a different 
chemical structure but attack the same ribosomal site for bacterial protein translation. 
Therefore, resistance against one agent frequently leads to cross-resistance against the other 
two. This fact is designated as MLSB resistance [73]. Antimicrobial binding at the 50S subunit 
of the ribosome causes an inhibition of the bacterial protein translation [73]. In S. suis, the 
major facilitator superfamily- or ATP-binding transporters, encoded by mef(A) and msr(D), 
respectively, mediate an increased antimicrobial efflux of macrolides and lincosamides [43, 63, 




MLSB resistance gene in S. suis [43, 63, 64]. This erythromycin rRNA methyltransferase 
methylates an adenine residue in the ribosomal 23S rRNA and prevents the binding of MLSB 
agents [74]. Unlike, erm(C) has been detected in S. suis only rarely [64]. The macrolide 
phosphorylase encoded by the gene mph(C), inactivates macrolides and has only rarely been 
identified in S. suis [64]. 
 
1.2.3 General characteristics of Bordetella bronchiseptica 
B. bronchiseptica are Gram-negative, obligate aerobic, rod-shaped coccobacilli [75]. 
They belong to the order Burkholderiales and the family Alcaligenaceae in the β-class of 
Proteobacteria [76]. The genus Bordetella comprises eight species that are mammalian or 
avian pathogens, with B. bronchiseptica, B. pertussis and B. parapertussis in a close genetic 
relation [77]. B. bronchiseptica colonizes the upper respiratory tract. B. bronchiseptica 
virulence is regulated by the Bordetella virulence gene locus (bvg) [78]. Good environmental 
conditions like a temperature of 37°C, low concentration of nicotinic acid or sulphate anions 
result in the activation of the bvg locus [79, 80]. Virulence factors that are expressed in this 
bvg+ phase facilitate B. bronchiseptica to infect the respiratory tract. In this phase the 
filamentous hemagglutinin, fimbriae, adenylate cyclase or dermonecrotic toxin are expressed 
[78, 81]. The dermonecrotic toxin impairs the osteoblast differentiation, which causes nasal 
atrophy in turbinate pig bones [82]. The name of the dermonecrotic toxin originates from its 
induction of necrosis in guinea pig skin after intradermal injection [83]. The bvg- phase is 
characterized by a reduced expression of virulence factors, which enables B. bronchiseptica 
to rest under limited nutritional conditions [79-81, 84]. Unlike to B. pertussis and 
B.  parapertussis, B. bronchiseptica is motile through peritrichous flagellation that is expressed 
in the bvg- phase [76, 85]. Overall, B.  bronchiseptica infects the respiratory tract of various 
animals and is transmitted through direct contact due to aerosol droplets of B. bronchiseptica 
carrying hosts, but also through indirect contact via infectious air over short distances [81, 86]. 
Pigs are one of the most predisposed species for B. bronchiseptica infections, especially in 
areas of intensive animal farming [75]. B. bronchiseptica can induce bronchopneumonia. In 
addition, they can also cause a mild form of atrophic rhinitis, but often serve as primary invader 
to predispose the respiratory tissue for a subsequent infection with toxin-producing 
P.  multocida [75, 76, 87]. B. bronchiseptica along with the canine parainfluenza virus are the 
main pathogens of kennel cough in dogs [75]. B. bronchiseptica can colonize humans and 
cause pneumonia in immunocompromised persons [88]. Furthermore, bronchopneumonia, 





1.2.4 Important antimicrobial resistance properties of B. bronchiseptica 
β-Lactam resistance in B. bronchiseptica is mediated by a species-specific 
chromosomally located β-lactamase producing blaBOR-1 gene that can be inhibited by clavulanic 
acid [89]. Additionally, some B. bronchiseptica isolates harbor a not species-specific class 1 
integron with a blaOXA-2 gene cassette, which is located on the chromosome or plasmids [90]. 
Kadlec et al. (2007) assumed that active efflux pumps do not play a role in ampicillin resistance, 
since their inhibition had no effect on bacterial susceptibility. The same study supposed a β-
lactamase-independent cephalosporin resistance based on reduced outer membrane 
permeability [90]. 
B. bronchiseptica is supposed to be susceptible to tetracyclines, although no clinical 
breakpoints approved by the Clinical and Laboratory Standards Institute (CLSI) are currently 
available [6, 91]. Nevertheless, B. bronchiseptica can harbor acquired, plasmid-located 
tetracycline resistance genes. These genes, tet(A) or tet(C), encode efflux pumps and 
commonly mediate a minimal inhibitory concentration (MIC) of ≥64 mg/L [92, 93]. The tet(A) 
gene is part of transposon Tn1721 and is coupled to the repressor gene tetR, which results in 
tetracycline-inducible expression of the Tet(A) efflux pump [93, 94]. 
The gene floR of B. bronchiseptica is chromosomally located and encodes an efflux 
pump that mediates resistance to chloramphenicol and florfenicol [95]. Furthermore, 
B.  bronchiseptica isolates were identified, which harbored the plasmid-borne gene cmlB1, 
which codes only for a chloramphenicol efflux pump. Chloramphenicol resistance in 
B.  bronchiseptica can also be mediated by the genes catB2 and catB3, which code for class 
B chloramphenicol acetyltransferases. These genes were identified on different class 1 
integrons, which were located either in the chromosomal DNA or on plasmids [96]. 
Gram-negative bacteria are thought to usually have a reduced susceptibility to 
macrolides, lincosamides and streptogramins of the B group (MLSB), due to their 
decreased outer membrane permeability for these classes of antimicrobials [97]. Moreover, 
many Gram-negative bacteria are associated with multi-drug efflux pumps that transfer harmful 
agents, e.g. antimicrobials, detergents or salts out of the cell. Among them, efflux pumps 
belonging to the resistance-nodulation-division (RND) family, play an important role. RND 
pumps obtain their energy from a proton-antiporter system [97, 98]. Resistance to MLSB 
antibiotics in Gram-negatives and Gram-positives can result from mutations that cause 
alterations in the V domain of the 50S ribosomal subunit of the 23S rRNA. These mutations 





1.2.5 General characteristics of Pasteurella multocida 
P. multocida belongs to the family Pasteurellaceae within the order Pasteurellales. This 
family includes many animal and/or human pathogenic genera, e.g. Mannheimia spp., 
Actinobacillus spp., Haemophilus spp. and Histophilus spp. [101]. P. multocida are Gram-
negative, rod-shaped coccobacilli [101]. P. multocida typing is based on their capsule, 
consisting of hydrophilic polysaccharides that are linked to the cell membrane. Carter (1955) 
established capsule typing by passive hemagglutination of erythrocytes with different 
P.  multocida capsule antigens. Hemagglutination has resulted into five different capsular 
serotypes, designated as A, B, D, E and F. The capsules of serotype A consists mainly of 
hyaluronic acid, those of serotype B of arabinose, mannose and galactose, the capsules of 
serotype D of heparin, and those of serotype F of chondroitin, whereas the capsules of 
serotype E are largely uncharacterized. Serotype C has not been confirmed yet and does not 
belong to the classification system anymore [102-107]. P. multocida colonizes mucosal 
surfaces, especially the respiratory and oropharyngeal tract in animals and is transferred 
between them through direct contact [103, 108]. P. multocida might act as primary pathogen 
or as secondary opportunistic pathogen by chance after a primary viral or bacterial infection, 
e.g. with B. bronchiseptica, has occurred [109, 110]. The capsule represents an important 
virulence factor that mediates adherence at cell surfaces and provides protection against 
phagocytosis and the host complement response [111]. Fimbriae, e.g. type IV, are responsible 
for adhesion at and colonization of the epithelium of the respiratory tract [112, 113]. Some 
P.  multocida isolates of serotypes D and sometimes type A, possess the toxA gene, which 
encodes the P. multocida-toxin (PMT) that belongs to the dermonecrotic toxin family [103, 
114]. Furthermore, PMT has similar properties like the described dermonecrotic toxin of 
B.  bronchiseptica [115]. Consequently, PMT also causes deformation of the pigs’ nasal bones. 
P. multocida infections are known to occur in many animals, e.g. pigs, cattle, rabbits, dogs, 
cats, birds and reptiles. P. multocida is also considered as a zoonotic pathogen [101, 108]. 
Human infections occur especially as local injuries through bites and scratches of cats or dogs, 
as pneumonia when humans are living in close contact to animals or rarely as systemic 
infections, especially in immunocompromised humans [116, 117]. PMT-producing P. multocida 
triggers the progressive form of atrophic rhinitis in pigs, which is indicated by purulent nasal 
discharge, sneezing and distorted turbinate bones [14]. Non-toxin producing serotype A 





1.2.6 Important antimicrobial resistance properties of P. multocida 
P. multocida isolates are considered to have a high susceptibility to antimicrobial agents, 
although a number of acquired resistance genes have been detected during the past 20 years 
[6, 118]. The resistance genes of P. multocida are commonly located on mobile genetic 
elements, mainly on plasmids. Plasmids of P. multocida that harbor antimicrobial resistance 
genes range in sizes between 4.3 to 11 kilobases (kb) [118-120]. The acquisition of resistance 
gene clusters can result in the development of multidrug-resistant bacteria through 
antimicrobial co-selection. A transfer of resistance genes commonly occurs within the 
Pasteurellaceae family, but also to other Gram-negative as well as Gram-positive bacteria 
[118, 121, 122]. 
β-Lactam resistance of P. multocida is usually mediated by β-lactamases. So far bla 
genes encoding ROB-1, TEM-1 and PSE-1 β-lactamases were detected [123-125]. Recently, 
an extended-spectrum β-lactamase gene, blaROB-2, was detected on a plasmid of a Mannheimia 
haemolytica isolate for the first time. Plasmid transformation experiments resulted in the 
plasmid uptake into P. multocida and mediated β-lactam resistance to them [126]. 
Energy-depended substrate specific efflux pumps of the major facilitator superfamily 
commonly meditate tetracycline resistance in P. multocida [118]. While genes coding for 
ribosomal protective proteins are less frequent. The most prevalent efflux pump detected in 
P.  multocida is encoded by the gene tet(H), which is coupled to a tetracycline depended 
repressor tetR [127, 128]. The tet(H) gene has first been described to be part of the composite 
transposon Tn5706, which was located on a plasmid. However, tet(H) genes have also 
identified in the chromosomal DNA and as parts of integrative and conjugative elements 
(ICEs), such as ICEPmu1 [129]. The genes tet(B), tet(G) and tet(L), all coding for tetracycline 
exporters, have also been found in P. multocida [125, 130, 131]. The gene tet(M) is the only 
tet gene that encodes a ribosomal protective protein in P. multocida [132]. 
Resistance to florfenicol and chloramphenicol of P. multocida is mediated by a plasmid-
located gene floR [133]. Resistance is to non-fluorinated phenicols can be conferred by the 
chloramphenicol acetyltransferase genes catA1, catA3 and catB2 [125, 134]. 
Aminoglycosides bind at the 30S subunit of the ribosome and inhibit protein translation. 
Aminoglycoside resistance can be either mediated by a (1) reduction of intracellular 
antimicrobial concentration, (2) the modification of the target site or (3) enzymatic inactivation. 
Enzymatic inactivation represents the only resistance mechanism against aminoglycosides in 
P.  multocida. The drug specific enzymes adenylate, acetylate or phosphorylate 
aminoglycosides and cause a structural aminoglycoside modification that makes the 




genes strA and strB are frequently detected in P. multocida [135]. Aminoglycoside-3ʼʼ-
phosphotransferase is encoded by strA, while strB codes for an aminoglycoside-6-
phosphotransferase. Furthermore, the genes aadA1, aadA14 and aadA25 mediate resistance 
to the combination of streptomycin and spectinomycin. The aadB and aacA4 genes confer 
gentamicin resistance and aphA1 as well as aphA3 mediates resistance to the combination of 
kanamycin and neomycin in P. multocida [125, 129, 136, 137]. 
Sulfonamides and trimethoprim (SXT) competitively inhibit the enzymes 
dihydropteroate synthase (DHPS) and dihydrofolate reductase (DHFR) of the folic acid 
biosynthesis pathway, respectively [138]. The antimicrobial effect is based on the prevention 
of bacterial growth caused by the lack of the essential folic acid. The genes sul2, dfrA14 and 
dfrA20 are the only detected sulfonamide and trimethoprim resistance genes in P. multocida 
and all three genes are commonly located on plasmids [120, 139, 140]. The gene sul2 encodes 
an insensitive form of DHPS that mediates resistance to sulfonamides, whereas dfrA14 and 
dfrA20 code for a DHFR that confers trimethoprim resistance. Moreover, sul2 is often plasmid 
associated together with strA and/or strB within the family of Pasteurellaceae [129, 135, 139, 
141]. 
 
1.3 Horizontal gene transfer among bacteria 
Vertical gene transfer is the transmission of the complete genome from one generation 
to the next. The complement DNA strand is transferred during cell division from a parent to a 
daughter cell. In contrast, horizontal gene transfer describes the transmission of pieces of the 
genetic information within a generation [142]. Transformation, transduction and 
conjugation/mobilization are processes of horizontal gene transfer. 
Transformation is defined as the uptake of free DNA that is located in the environment 
of competent bacteria. These incorporated DNA segments can originate from viruses or 
bacteria [143]. This process allows intra- and inter-species gene transfer, including an uptake 
of antimicrobial resistance genes. External DNA fragments can be integrated as plasmids, 
whole genes or just parts of genes into the host genome via recombination events [143]. 
Transduction describes the gene transfer, mediated by bacteriophages. Phages 
represent viruses that are specialized to infect bacteria or archaea [143]. Lytic bacteriophages 
reproduce themselves only in the lytic cycle, whereas temperate bacteriophages multiply 
themselves during the lysogenic and lytic cycle. During the lytic cycle, phages decompose host 
DNA into nucleotides to use them for their own phage DNA reproduction. During assembling 




into phage capsids by accident. This process is called generalized transduction. In contrast, 
specialized transduction occurs during the lysogenic cycle. Thereby, phage DNA is integrated 
into the bacterial chromosome. In the first phase of this cycle, phage reproduction is coupled 
to the host cell division. After extracellular stimulation, the lysogenic cycle changes to a lytic 
cycle. Bacteriophage DNA, also occasionally including flanking bacterial genes, is excised 
from the chromosome and integrated into newly assembled bacteriophage particles [143, 144]. 
For conjugation a cell-to-cell contact is needed for the formation of a pore to transfer 
bacterial DNA, e.g. plasmids, transposons or ICEs, from a donor cell to a recipient cell [143]. 
Genetic information for potential conjugation is encoded on conjugative plasmids and 
transposons, as well as on ICEs. Conjugation may occur between bacteria of the same or 
different species and genera, especially within biofilms [143]. Plasmids are extrachromosomal, 
mostly circular elements that consist usually of double-stranded DNA. They are capable of 
autonomous replication. Plasmids can have a size between 1 to 400,000 kb. Bacteria may 
harbor a different number of plasmids that are distinguished in low- and high-copy plasmids. 
Low-copy plasmids are commonly large plasmids with only one or few copies per bacterial cell, 
whereas high-copy plasmids are smaller plasmids with usually >100 copies per bacterial cell 
[142, 145]. Conjugative plasmids harbor the transfer (tra) gene complex, which carries the 
information for all necessary conjugation proteins. Conjugative and mobilizable plasmids have 
an origin of transfer (oriT) at which the separation of the two DNA strands starts during 
conjugation/mobilization. In contrast, the origin of vegetative replication (oriV) represents the 
start of the replication of non-conjugative plasmids [143, 146]. Furthermore, conjugative 
plasmids often encode a relaxase, a type IV coupling protein (T4CP) and a type IV secretion 
system (T4SS) [143, 147]. The relaxase binds at the oriT within the donor cell and induces the 
cleavage of the double-stranded DNA. The connected complex of relaxase, DNA-strand and 
T4CP form the relaxosome and become linked to the T4SS. The T4SS forms a protein cylinder 
that connects the donor cell with the recipient. During conjugation, one single DNA strand 
remains in the donor cell, while the other one is transported across the pore forming T4SS into 
the recipient. The complementary strands are synthesized during conjugation in both cells 
through the DNA polymerases [143, 146]. While conjugative plasmids are self-transmissible, 
mobilizable plasmids are only transmissible by the help of conjugative elements located 
within the same cell. Mobilizable plasmids only harbor mob genes, e.g. mobA, mobB and 
mobC, that encode components of the relaxosome forming unit, but no parts of the secretion 
system [148, 149]. MobA is the relaxase that forms a complex with oriT. MobC supports the 
relaxase to cleave the double stranded-DNA at the oriT site into a single strand. Furthermore, 
MobB stimulates MobC to get active and stabilize the relaxosome [149]. Finally, the carrier of 




antimicrobial resistances, toxins or virulence factors. Those genes might provide advantage in 
bacterial survival during challenging environmental conditions. 
 
1.4 VASIB project 
VASIB is a collaborative project between different partners of the University of Veterinary 
Medicine Hannover, the Friedrich-Loeffler-Institute, the Vet team Reken and the Freie 
Universität Berlin. The title is an acronym deduced from the German project title and includes 
the projects’ aim to reduce the antimicrobial consumption in pig production by integrating 
epidemiological information from consulting expertise in clinic, hygiene, microbiology and 
pharmacology. For this reason, 30 porcine farrow-to-finish farms, with a history of recurring 
respiratory tract infections were investigated. The environment of the weaners with an age of 
four to ten weeks was evaluated. Therefore, dust, water and feed samples were taken to 
measure antimicrobial residues. Furthermore, blood and bronchoalveolar lavage fluid (BALF) 
samples were taken from the weaners. While blood was examined for the concentration of 
antimicrobial agents, BALFs were analyzed for respiratory tract pathogens and antimicrobial 
residues. The farrow-to-finish farms were sampled at different time points A to F: 
· (A) The weaners were healthy and four of them were sampled. 
· (B) The weaners showed respiratory tract problems and three of these were 
sampled before starting the antimicrobial treatment. 
· (C) The same three weaners as in B were tested at the last day of antimicrobial 
treatment, five to seven days after time point B. 
· (D) The weaners showed respiratory tract symptoms yet again and three pigs were 
sampled before the antimicrobial treatment.  
· (E) The same three weaners from time point D were tested at the last day of 
antimicrobial treatment. The animals of time points B/C and D/E were not the 
same, since the collection time between them were four to seven months. 
· (F) Four healthy pigs were sampled at the final visit, approximately one year after 
visit A. 
The aims of the microbiological part of the VASIB project and also of this thesis were 
to: 
· examine the antimicrobial resistance profiles of the pathogens in each farm 




· determine the degree of relationship of members of each bacterial species within 
selected farms at different collection time points as well as between farms; 
· detect antimicrobial resistance mechanisms of bacteria by studying resistance-
mediating plasmids, acquired resistance genes or amino acid alterations in 
resistance-mediating proteins; 
· clarify possible resistance gene transfers or shifts in the bacterial resistance 
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2.4 Unpublished data 
Publication I gives an impression on the relatedness and antimicrobial susceptibility of 
S. suis, B. bronchiseptica and P. multocida only in Farm 1 and Farm 2, while Publications II
and III display specific resistance mechanisms on certain farms. In order to gain a more precise 
overview on the antimicrobial susceptibility of the pathogens, we added the unpublished MIC 
data tables 1, 2 and 3 of S. suis, B. bronchiseptica and P. multocida, respectively, from all 




































































































































































































Unpublished data Table 1 MIC distribution of S. suis isolates (n=257) from all examined farms to important antimicrobials of this project. The vertical green 



































































































































































































Unpublished data Table 2 MIC distribution of B. bronchiseptica isolates (n=20) with one isolate per farm that harbored B. bronchiseptica. Important 


































































































































































































Unpublished data Table 3 MIC distribution of P. multocida isolates (n=39) with one or two isolates per farm that were distinguishable due to their serotype. 





This doctoral thesis is focused on the determination of the antimicrobial susceptibility of 
the aforementioned respiratory tract pathogens in the context of 30 farrow-to-finish farms. In 
addition, the genetic relatedness of selected S. suis, B. bronchiseptica and P. multocida 
isolates was investigated. The genetic relatedness of the pathogens on farm level as well as 
between farms and the antimicrobial susceptibility is presented in Publication I. Publications 
II and III provide detailed information on some P. multocida and S. suis isolates, exhibiting SXT 
resistance and differences in penicillin susceptibility, respectively. 
The examined weaners frequently harbored S. suis, whereas P. multocida and 
B. bronchiseptica were present in lower numbers. This observation was in agreement with the
results of other studies, in which S. suis was detected with a prevalence of 98 % in the porcine 
upper respiratory tract [150, 151]. In contrast, the average isolation rate of B. bronchiseptica 
from porcine lung samples was 18.6 % [152]. The studies of MacInnes et al. (2008) and Zhao 
et al. (2011) looked only for toxigenic P. multocida and the latter one determined a low herd 
prevalence of PMT-producing P. multocida. The study of Zhao et al. (2011) detected toxin-
producing P. multocida only in low numbers, but always in association with B.  bronchiseptica. 
However, the P. multocida isolates of the VASIB study were investigated only for their serotype 
and not for PMT production. The porcine respiratory tract is colonized by mixed cultures of 
commensal bacteria such as S. suis, H. parasuis or Mycoplasma hyorhinis [14]. Especially 
A. pleuropneumoniae and Mycoplasma hyopneumoniae, but also toxin-producing
P. multocida or B. bronchiseptica may act as primary bacterial pathogens. Therefore, the
identification of the causative pathogen, which triggers the respiratory tract infection, may be 
difficult. Furthermore, different bacterial species show different intrinsic and acquired 
antimicrobial resistances, which complicates the selection of effective antimicrobial agents that 
act against the causative respiratory tract pathogens. In the VASIB study, pigs from 20 of the 
30 examined farms showed respiratory tract symptoms. This resulted in the therapeutic 
application of antimicrobial agents. In four of the aforementioned 20 farms, respiratory tract 
diseases reoccurred at a later stage. In total, antimicrobial agents were prescribed and applied 
24 times on farms for five or seven days. Doxycycline was used most frequently (14 times). 
Amoxicillin was prescribed eight times, whereas each combination of amoxicillin/clavulanic 
acid and tiamulin/florfenicol was applied only once. In order to gain more information about the 
effects of the prescribed antimicrobial agents, we focused on the MIC results of S. suis, 
B. bronchiseptica and P. multocida towards tetracyclines, β-lactams, tiamulin and florfenicol.
Moreover, we looked in retrospect on the pathogen MICs towards the prescribed antimicrobials 
and tried to interpret the results as well as indicate better antimicrobial therapy options, since 




A modified clinical score system of Höltig et al. (2008) was used to determine the effect of the 
antimicrobial therapy on the health status of the pigs. This score value identified a successful 
antimicrobial treatment in 21 of the 24 farms with porcine respiratory tract infection (Table S1) 
[153]. In three farms, no improvement or even a deterioration of the health status of the pigs 
occurred after doxycycline (n=2) and amoxicillin (n=1) therapy. The cross-sectional study of 
van Rennings et al. (2015) about the antimicrobial treatment within a one-year period identified 
amoxicillin (2.2 t) as the most frequently prescribed antimicrobial agent in weaner pigs suffering 
from respiratory tract infections in German pig farms in 2011. Tetracycline (1.1 t) and 
chlortetracycline (0.64 t) were the second and third most frequently used antimicrobial agents, 
followed by sulfadiazine (0.52  t) [15]. Even the BVL reported on the highest sales of penicillins 
(269 t), followed by tetracyclines (188 t), polypeptide antibiotics (74 t) and sulfonamides (62 t) 
in the total amount of prescribed veterinary antimicrobials, in Germany in 2017 [2]. These 
reports are in accordance with the antimicrobials used in the VASIB study, since doxycycline 
belongs to the antimicrobial class of tetracyclines and amoxicillin and amoxicillin/clavulanic 
acid to the β-lactams. This study represents a snapshot of 30 examined porcine farrow-to-
finish farms. In ten farms, weaners showed no respiratory tract infections, whereas other farms 
had up to two veterinary visits, B/C and D/E, during which antimicrobial agents were prescribed 
and applied. 
 
3.1 Genetic relatedness of S. suis at farm level and between different farms 
In the following explanations, isolates are designated as members of the same clones, 
when they shared indistinguishable PFGE patterns as confirmed by cluster analysis using the 
Unweighted Pair Group Method with Arithmetic Average (UPGMA) analysis [12, 154, 155]. 
PFGE patterns were designated as closely related with an identity of ≥80 % according to the 
UPGMA analysis [12, 154, 155]. Closely related isolates might have developed over time from 
a common ancestor [12, 13]. Unrelated PFGE patterns differed in up to seven fragments [12]. 
Publication I showed the results of the macrorestriction with subsequently PFGE analyses. 
Up to two or more S. suis isolates with different PFGE patterns were detected within a 
pig barn at the same time point (Publication I). The study of Vela et al. (2003) already 
confirmed the presence of a variety of S. suis isolates among diseased pigs within the same 
herd. Diseased pigs of that study had symptoms of meningitis, septicemia, pneumonia, 
pericarditis or arthritis. In contrast, the pigs of the VASIB study were apparently healthy or 
showed mild respiratory tract symptoms. The results of the VASIB study revealed that 
weaners, who lived in separate boxes of the same barn were positive for the same S. suis 




through direct or indirect transmission events. The weaners seem to become infected with 
S.  suis during birth by contact with the maternal genital tract [157]. Moreover, nasal contact 
between the pigs is known to be the most important transmission route, since S. suis is 
commonly located in the upper respiratory tract. S. suis may also be transferred via contact 
with contaminated skin wounds and feces [19]. Berthelot-Hérault and colleagues (2001) 
confirmed experimentally the airborne transmission of pathogens from a S. suis infected pig 
herd to a specific pathogen-free herd that had no contact, but was located in a distance of 
40  cm. Hence, the study of Berthelot-Hérault et al. (2001) may explain airborne S. suis spread 
across pig boxes. Furthermore, S.  suis may be transferred via contaminated dust, water or 
feed [19]. The study of Dee and Corey (1993) displayed the survival of S. suis at farm surfaces 
and veterinary equipment. The highest survival rate was measured on manure contaminated 
rubber or plastic at room temperature, thus rubber boots, buckets or needles are described as 
probable sources of pathogen transfer. However, one of these possible transfer routes may be 
responsible for the appearance of S. suis clones in weaners without direct contact at the 
moment of the sampling. Moreover, the pigs had been rearranged after the end of the farrowing 
period, and were newly assembled into groups for the nursery as well as fattening periods [8]. 
Here, weaners of different litters were brought together with the consequence of a probable 
isolate exchange. This might explain the presence of different S. suis clones in different pig 
boxes. Single pigs harbored up to two or three S. suis isolates with different PFGE patterns 
(Publication I). This leads to the conclusion that unrelated S. suis isolates are able to coexist 
at the same time in the same sampling site within the same pig. The majority of the detected 
S. suis isolates seems to be commensals, since only 14.0 % (n=36) of all examined isolates 
(n=257) belonged to the most pathogenic serotypes 1, 2, 7 and 9 (data not shown), concluding 
that the other isolates belong to the less pathogenic serotypes [158]. This might be an 
explanation for the occurrence of only slight respiratory tract symptoms of the pigs. It has been 
shown that less virulent or avirulent isolates cause mild diseases or result in apparently healthy 
carrier pigs [19, 23]. The S. suis isolates, which were obtained within the one-year sampling 
period at the different time points (A - F), revealed PFGE patterns that differed from those of 
isolates of earlier sampling time points (Publication I). Allgaier et al. (2001) determined the 
relatedness of S. suis based on macrorestriction analysis from healthy and diseased pigs and 
suggested a higher clonal relatedness of virulent S. suis strains causing meningitis or arthritis. 
A higher PFGE diversity was observed among the less virulent isolates that caused pneumonia 
or were detected in apparently healthy carrier pigs [159]. This genetic diversity of S. suis was 
confirmed in the VASIB study as shown in the different S. suis PFGE patterns seen at Farms 
1 and 2 in Publication I. Besides, the isolates of the present study were obtained from BALF 
samples of apparently healthy carrier pigs and those with mild respiratory tract symptoms. 




among S. suis isolates obtained from these pigs. The occurrence of unrelated S. suis isolates 
at earlier sampling time points raises the question how the previously not identified isolates 
were imported into the farms. Since the 30 examined farms in this project were farrow-to-finish 
farms, no weaners from other farms were purchased before the start of a new production stage. 
That excludes an import of new isolates from bought fattening pigs. However, the different pig 
barns undergo a constant pig flow, since the sows give approximately 2.34 litters a year and 
thus, the different groups of piglets will change the barns according to their production stage 
[9]. Moreover, the examined pigs of this study were at an age of four to ten weeks. The 
sampling (A - F) occurred at the end of the nursery or start of the fattening period in different 
barns. In conclusion, the pigs in different fattening cycles and at time points A, B/C, D/E or F 
should have their own bacterial population. This still leaves the question, how S. suis isolates 
with different PFGE patterns in the same sampled pigs of time points B/C or D/E occurred. 
New isolates might have existed in undetectable numbers in the pigs’ habitat and after changes 
of environmental conditions, like antimicrobial therapy, these new isolates might have replaced 
others. However, in Farm 2 some closely related isolates were identified at different sampling 
time points. In addition, clones were detected at different sampling times within six to twelve 
month periods of time between the samplings within single farms (Publication I, Figure S1 
and Figure S2). This indicates a long-term survival of these isolates on single farms. As already 
introduced, the closed farm system is characterized by a low bacterial import from the outside. 
However, the spread of bacteria within closed farms is supposed to be much higher, due to 
lower barrier restrictions between the different rearing phases of the pigs [7]. Another reason 
for the appearance of clones or closely related isolates in different pig herds on farm level 
might be the bacterial transfer between sows and their piglets. Sows of a production cycle, 
especially during the gestation period, live in a close contact to each other [8]. Hence, bacteria 
can be transferred across the whole group of sows. Weaners originating from sows of the 
same production cycle may have been perinatally colonized with bacteria from their parents 
[157]. Some other reasons for the occurrence of closely related isolates over a long time period 
might be caused by farm specific deficiencies in hygiene that enable a transmission or survival 
of the bacteria. Hygienic deficiencies may be insufficient concentrations of detergents or 
disinfectant agents or a reduced effect of the disinfectant agent after an insufficient cleaning, 
thus protein waste may remain in a pig barn. This protein waste may coagulate and enclose 
pathogens after their contact with disinfectants. Protein enclosed pathogens are protected 
against antiseptic effects and survive the cleaning and disinfection steps.  
The comparison of S. suis PFGE patterns of different farms revealed a wide variety of 
macrorestriction patterns among the isolates (data shown in parts in Figure S1 and Figure S3) 




clones were also identified in different farms in the VASIB study (Figure S3). However, the 
same clone was detected only in a maximum of two farms. Hence, each farm couple, Farms 2 
and 14, Farms 3 and 25 as well as Farms 20 and 30 showed the presence of their own S. suis 
clones. Vela et al. (2003) detected isolates with similar PFGE patterns on several farms and 
suggested that those isolates might have a higher pathogenic potential. However, in the six 
examined farms that harbored these three S. suis clones, a mild respiratory tract infection 
occurred in several weaners. Moreover, only the clone of Farms 20 and 30 belonged to the 
pathogenic serotype 7. The clones of Farms 2 and 14 as well as Farms 3 and 25 did not belong 
to the pathogenic serotypes 1, 2, 7 or 9 [25, 158]. Berthelot-Hérault et al. (2002) identified a 
high genetic diversity, according to the macrorestriction patterns, among S. suis isolates of 
serotypes 2 and 7 obtained from diseased pigs and humans. However, a higher similarity of 
the PFGE patterns of each serotype 1/2, 3 and 9 was observed in the same study [160]. Blume 
et al. (2009) examined serotypes 2 and 9 of diseased pigs and recognized a high genetic 
diversity among them. Nevertheless, three different PFGE profiles of serotype 9 and two 
different profiles of serotype 2 were frequently isolated in different herds in several Spanish 
provinces, indicating a wide distribution of genetically related pathogenic isolates [161]. 
However, clones that were identified in different farms in the VASIB study might indicate 
possible transfer ways. Since no new weaners were purchased from other farms or markets, 
the replacement of sows within farms might be the reason for the import of new pathogens. 
Sow longevity in intense animal farms depends individually on their litter size, age, gestation 
rate, udder and leg fitness [162]. In case, sows of the same multiplier farms were purchased 
by different farrow-to-finish farms, they might be carriers of bacteria with similar PFGE patterns 
and peri- or postnatally transmit these bacteria to their piglets. Only six of the 30 examined 
farms in the VASIB project, produced their own gilts. Each of the remaining 24 farms purchased 
their gilts from one or two multiplier farms. Unfortunately, whether or not the different farrow-
to-finish farms obtained their gilts from the same or from different multiplier farms was not 
included in the questionnaire that was prepared for the farm workers at the first sampling at 
time point A. 
 
3.2 Genetic relatedness of B. bronchiseptica at farm level and between different 
farms 
In Publication I, all B. bronchiseptica isolates obtained from the same pig showed 
indistinguishable PFGE patterns. This is in contrast to the results observed for S. suis, where 
an individual pig may harbor S. suis with different PFGE patterns. Furthermore, only one 




same farm (Publication I). Binns et al. (1998) examined B. bronchiseptica, especially from 
cats, by macrorestriction analysis. They grouped the isolates, according to their PFGE 
patterns, into 17 strains (A-Q), each of them differed by at least four fragments from the others 
[163]. Furthermore, the strain designation included subtypes that differed in up to three 
fragments to a strain. Most B. bronchiseptica of the cats belonged to strains A and B, which 
showed a low diversity in their PFGE patterns. If we follow the classification scheme of Binns 
and colleagues (1998) for strain and subtype classification, the B.  bronchiseptica isolates from 
Farms 1 and 2 of Publication I would be classified as representing the same strain. 
Furthermore, the one clone of Farm 1 and the two clones of Farm 2 would belong to three 
different subtypes of that strain, since they differed in up to one or two fragments from each 
other. Binns et al. (1998) determined that cats, who had lived in the same household harbored 
B. bronchiseptica isolates of the same strain. This observation is also confirmed by the results 
of the VASIB study, since the isolates of an individual farm all represented the same strain. In 
addition, the isolates of both farms that were investigated in Publication I also represented 
the same strain. 
Furthermore, we compared the B. bronchiseptica PFGE patterns of seven different farms 
(Figure S4). These seven farms include the isolates of Farms 1 and 2 (Publication I), which 
were obtained over a one-year period and the isolates of five farms, which were collected at 
sampling time point A. This analysis revealed the occurrence of one individual clone per farm. 
Nevertheless, these individual clones from the different farms were closely related to each 
other (Figure S4). Shin et al. (2007) examined porcine B. bronchiseptica isolates and classified 
them, similar to Binns et al. (1998), into three strains (A-C) with their subtypes. Most isolates 
of his classification belonged to strains A and B. So, they also observed a low genetic diversity 
among porcine B. bronchiseptica isolates [164]. We can confirm this low genetic diversity, 
since even the B. bronchiseptica isolates of the seven different farrow-to-finish farms revealed 
closely related PFGE patterns. Furthermore, the B. bronchiseptica isolates of the study from 
Shin et al. (2007) originated from two adjacent provinces in Korea. The B. bronchiseptica 
isolates of the one province were classified only as strain A, whereas the isolates of the other 
province represented strains A and B [164]. This result might indicate that in certain 
geographical areas a limited number of strains occur. However, Shin and colleagues (2007) 
pointed out that a larger number of B. bronchiseptica isolates from different areas is needed 
to confirm this hypothesis. Nevertheless, the results of the present study would agree with this 
finding, since the closely related isolates of the seven different porcine farrow-to-finish farms 
originated from the Western part of Germany. Based on the close genetic relationships of the 
B.  bronchiseptica isolates seen in all seven farms, it is likely that the isolates of the different 




as other studies showed that B. bronchiseptica isolates often displayed related PFGE patterns, 
which may be indicative of a comparatively low heterogeneity of porcine B. bronchiseptica 
isolates [96, 163-165]. 
 
3.3 Genetic relatedness of P. multocida at farm level and between different 
farms 
PFGE analysis of P. multocida isolates showed different patterns at each sampling time 
point as exemplarily shown for Farm 2 of Publication I. In contrast to the situation seen for 
S.  suis, each investigated pig carried only a single P. multocida clone (Publication I). This 
observation is in accordance with a French study that detected isolates with indistinguishable 
PFGE patterns from the same pig [166]. While the PFGE results of Farm 2 suggest only one 
clone per time point within a pig barn, further examinations yielded other results. Namely, 
isolates with different PFGE patterns were detected at the same sampling time point among 
different animals within the same farm (Figure S5). In addition, five of the 29 farms, in which 
P. multocida was found among the pigs, harbored isolates belonging to serotypes A and D or 
A and B at the same time (data not shown), suggesting the presence of at least two genetically 
different P. multocida isolates at the same time within a pig herd, but not within the same 
animal. These results are similar to the result of Marois et al. (2009), who identified four 
different P. multocida PFGE patterns at the same time within a farm, but also not within the 
same animal. 
The comparison of PFGE patterns of P. multocida isolates from different farms illustrates 
the occurrence of diverse isolates per farm (Figure S6). Nevertheless, some isolates were 
closely related in their PFGE patterns (identity of 82.5 % to 97 %) to isolates of other farms as 
shown in Publication II and Figure S6. Similar to this, the French study of Marois et al. (2009) 
identified isolates with indistinguishable PFGE patterns in three different farms. However, the 
closely related isolates in different farms of the VASIB study belonged to the same serotype A 
or D, respectively. However, not all isolates belonging to the same serotype showed closely 
related PFGE patterns (Figure S6). Some studies about the genetic relatedness of 
P.  multocida of porcine, human or avian origin assumed a limited number of clonal lineages 
within their specific hosts, especially within certain regions [166-169]. As already mentioned 
for B.  bronchiseptica, P. multocida isolates were classified in those studies into strains and 
subtypes [163]. The Danish study of Pors et al. (2011) examined 139 P. multocida isolates and 
grouped them into 13 PFGE strains each with subtypes and observed the highest prevalence 
of serotype A and sequence type (ST) 13. We examined only the isolates of Publication II for 




the present study. From the 101 P. multocida isolates examined in the VASIB study, 69.3 % 
(n=70) belonged to serotype A, whereas 27.7 % (n=28) were type D and 3.0 % (n=3) type B. 
Isolates of the VASIB study originated from apparently healthy and diseased pigs, whereas 
the isolates examined in the Danish study were obtained from bronchopneumonia lesions of 
pigs at slaughter houses [167]. Bronchopneumonia is most frequently associated with serotype 
A, that may explain the higher occurrence in the Danish study. P. multocida isolates presented 
in Publication II were identified as serotype A and ST13, assuming a higher prevalence of this 
lineage in pigs. However, these isolates of this lineage were not only detected in diseased 
pigs, they were also identified in clinically healthy pigs in the VASIB study, which might provide 
hints towards their commensal character. However, P. multocida were not investigated in the 
VASIB study for the presence of virulence genes and conclusions about their virulence are 
only speculative. In conclusion, some studies seem to indicate the existence of certain clonal 
lineages of P. multocida within specific geographical areas, as noticed in Denmark or Vietnam 
[166, 167]. This observation may explain the occurrence of a limited number of P. multocida 
lineages in Germany, which is confirmed by the presence of closely related isolates in different 
farms of the VASIB project (Figure S6). Thus, porcine P. multocida isolates display a moderate 
genetic heterogeneity, which is in contrast to the broad genetic diversity observed in porcine 
S. suis and the great genetic homogeneity seen in porcine B. bronchiseptica. 
 
3.4 Antimicrobial susceptibility of S. suis 
S. suis isolates with indistinguishable PFGE patterns exhibited MIC values of 
antimicrobial agents that were rather similar and differed from each other in only +/- one dilution 
step (Publication I). Accordingly, isolates with closely related, but not identical PFGE patterns 
showed differences in their MIC values as well. Isolates with PFGE patterns that were more 
different, and hence not related with each other showed rather different MICs. This led us to 
the conclusion, that an antibiogram for only one S. suis isolate per pig farm is not sufficient to 
extrapolate the susceptibility to antibiotics of the S. suis isolates of the entire farm. Genetically 
different S. suis isolates were present at the same time within a farm as well as within an 
animal and these isolates may exhibit different antimicrobial susceptibility patterns. However, 
performing macrorestriction analysis before generating an antibiogram is too expensive and 
too time consuming. In order to capture a more complete picture of the variable antimicrobial 
susceptibility of S. suis isolates, diagnostic laboratories should pay attention on differences in 
morphology of capsule expression or α-hemolysis and then decide to conduct antibiograms of 




The distribution of S. suis MIC values observed in Farm 1 (n=7) and Farm 2 (n=15) of 
Publication I corresponds to the MICs of all examined farms in which S. suis (n=257) was 
detected in the VASIB project (unpublished data Table 1). The MIC90 of 128 mg/L indicated 
that the vast majority of the tested S. suis isolates was resistant to tetracyclines (unpublished 
data Table 1). This result is comparable with the results of the GERM-Vet and VetPath studies, 
where the S. suis isolates from diseased pigs showed tetracycline MIC90 values of 64 mg/L [5, 
65]. Tetracycline CLSI breakpoints of S.  suis are applicable only for injectable formulations 
[91]. However, antimicrobial agents in pig industry are usually applied through feed or water. 
There is no information about how the CLSI-approved clinical breakpoints and the tetracycline 
concentration in the respiratory tract tissue after oral tetracycline application correlate with 
each other. Hence, the bacteriostatic effect of tetracyclines may fail, if the antimicrobial 
concentration is too low in the respiratory tract tissue. Moreover, doxycycline was the most 
prescribed antimicrobial agent in the VASIB study. However, there is no doxycycline-specific 
clinical breakpoint for S. suis from swine. Although tetracycline is considered as the class 
representative, it is questionable whether the tetracycline breakpoints can be applied for 
doxycycline. In staphylococci, the doxycycline-specific breakpoints for Staphylococcus 
pseudintermedius are one dilution step lower than the tetracycline-specific breakpoints for 
Staphylococcus spp. (including S. pseudintermedius). In the VASIB study doxycycline MIC50 
and MIC90 were 8 mg/L and 16 mg/L, respectively. Bearing in mind that the S. suis-specific 
tetracycline breakpoint for resistance is at ≥2 mg/L, most of the S. suis isolates in the VASIB 
study may be regarded as doxycycline-resistant. Isolates classified as tetracycline- and 
doxycycline-resistant (n=205) harbored tetracycline resistance genes tet(O) with 57.6 %, 
tet(M) 14.1 %, tet(L) 2.4 % and tet(W) 3.9 %. In 22.0 % of the S. suis isolates, none of the 
examined tetracycline resistance genes was detected, assuming the presence of another 
tetracycline resistance-mediating gene. The presence of tetracycline resistance genes might 
indicate reduced effects on pig recovery during doxycycline therapy. However, the doxycycline 
therapy was only in two farms unsuccessful, as indicated by the modified diagnostic respiratory 
score system [153]. Besides, in pigs of twelve of the fourteen farms, where doxycycline was 
applied, tetracycline-resistant S. suis were detected at the last day of antimicrobial treatment 
(Table S1). Anyway, doxycycline usage leads to a high selection pressure under which isolates 
with tetracycline resistance genes can persist. 
MIC90 values of 0.12 mg/L confirmed an overall good susceptibility of S. suis (n=257) to 
ampicillin. The S. suis-specific clinical breakpoint for ampicillin is at ≤0.5 mg/L. For the 
combination amoxicillin/clavulanic acid, a MIC90 value of 0.06/0.03 mg/L was determined 
(unpublished data Table 1). The aforementioned MIC90 values from the VASIB study are in 




0.06/0.03  mg/L, respectively [65]. The GERM-Vet study only determined the MIC90 of 
ampicillin with ≤0.5 mg/L [5]. In contrast, most of the isolates of the VASIB study were classified 
as intermediate to penicillin with a MIC90 value of 0.5 mg/L (unpublished data Table 1), whereas 
no penicillin MICs were determined in the VetPath and GERM-Vet studies [6, 65, 91]. In 
addition, 24 isolates originating from different farms and animals in the VASIB study showed 
a penicillin-resistance phenotype. Reduced penicillin susceptibility of S. suis isolates was 
already reported almost 30 years ago and is still discussed [43, 64, 170]. In order to gain more 
information on S. suis with reduced penicillin susceptibility, three isolates that were 
susceptible, intermediate and resistant to penicillin were subjected to whole genome sequence 
analysis. Their sequences were investigated for structural variations in the PBPs and the 
results presented in Publication III. The lowest number of amino acid alterations in their PBPs, 
as compared to S. suis BM407 (accession number FM252032.1), were identified in the 
penicillin-susceptible isolate IMT40343, whereas the penicillin-intermediate isolate IMT40201 
and the penicillin-resistant isolate IMT40738 exhibited distinctly more amino acid alterations. 
These findings suggest that even in S. suis, alterations in their PBPs mediate reduced 
susceptibility to penicillins as already detected in S.  pneumoniae [58, 59]. Furthermore, the 
lowest amino acid alterations were identified in PBP1a, PBP1b and PBP2a of IMT40343 and 
IMT40201. The penicillin-resistant isolate IMT40738 and the intermediate isolate IMT40201 
had the highest number of amino acid substitutions in PBP2x and PBP2b, while IMT40738 had 
additional amino acid alterations in PBP2a. Limited information exists about the effects of 
amino acid alterations in the PBPs of S.  suis [42, 43]. As a consequence, the information from 
the well-examined human pathogen S. pneumoniae was transferred to S. suis. Mosaic genes 
as identified in S. pneumoniae were not confirmed in the examined PBPs of S. suis in our study 
[50-52]. S. pneumoniae exhibits a moderate β-lactam resistance while having substitutions in 
PBP2x or PBP2b, whereas high level β-lactam resistance in S. pneumoniae is additionally 
mediated by alterations in PBP1a [58, 59]. Since S. suis isolate IMT40738 is penicillin-resistant 
with a MIC of 2 mg/L and intermediate to ampicillin and ceftiofur, we suggest a moderate β-
lactam resistance. The S.  suis isolate IMT40201 exhibited an intermediate MIC to penicillin 
and was classified as susceptible to ampicillin and ceftiofur. This leads us to the conclusion 
that amino acid alterations in PBP2x and PBP2b in S. suis reduce the penicillin susceptibility. 
Moreover, additional alterations in other PBPs, like in PBP2a in S. suis of this study or in 
PBP1a in S.  pneumoniae, seem to mediate a reduced susceptibility to the remaining β-
lactams [55, 58]. Moreover, no amino acid alterations were detected in the conserved motifs 
of all PBPs in this study. This is in contrast to other studies of S. pneumoniae, where an 
alteration within the conserved motif Ser-X-X-Lys of PBP1a was described, which led to a 
reduced susceptibility to penicillin [58]. Smith et al. (1998) identified a substitution from Thr371 




affinity. Hu et al. (2011) observed a substitution in PBP2x close to a conserved motif in a β-
lactam-resistant S. suis and assumed an effect on its reduced β-lactam affinity. Smith et al. 
(1998) also suggested another important substitution of four amino acids in S. pneumoniae 
downstream of the Lys-Thr/Ser-Gly motif of PBP1a that could led to a reduced penicillin affinity, 
but we could also not detect this alteration in the isolates of our study. The lack of finding 
similar amino acid substitutions, which were already described in other studies, led to the 
suggestion that some other amino acid alterations within the PBPs of S. suis may confer a 
change in charge and reduce the affinity to β-lactams. However, to have an evidence for that, 
transformation and cloning experiments would be necessary. Besides, the serotypes of the 
sequenced isolates indicate that these S. suis belong to the less pathogenic, rather commensal 
flora of the respiratory tract. Hence, the more frequently occurring commensals might 
accumulate mutations in their PBPs and represent a source of resistance genes for pathogenic 
isolates. 
The S. suis isolates showed a florfenicol MIC90 value of 2 mg/L (unpublished data Table 
1). Since 2 mg/L was the highest florfenicol MIC value measured, all S. suis isolates of the 
VASIB study were classified as florfenicol-susceptible according to the CLSI breakpoints [91]. 
The same MIC90 value was detected in the VetPath study, indicating a high susceptibility of 
S.  suis to florfenicol and no presence of florfenicol resistance genes. In veterinary medicine, 
florfenicol formulations are approved for pigs via injection, as well as feed and water 
supplement with an average withdrawal period of 20 days after the last antimicrobial 
application. Nevertheless, these formulations are only approved for the treatment of respiratory 
tract infections in swine caused by florfenicol-susceptible isolates of A. pleuropneumoniae and 
P. multocida [68]. 
As already displayed in Publication I, tiamulin showed a wide range of MICs with a 
MIC90 of 32 mg/L (n=257) (unpublished data Table 1). Unfortunately, no tiamulin CLSI 
breakpoints are available for S. suis, but the high MIC values to tiamulin indicate a reduced 
effect on S. suis and hence, tiamulin should not be used for therapeutic interventions of 
respiratory tract infections caused by S. suis. 
 
3.5 Antimicrobial susceptibility of B. bronchiseptica 
MIC values of B. bronchiseptica are difficult to interpret, since CLSI breakpoints are 
available for only four antimicrobial agents – ampicillin, tulathromycin, tildipirosin, and 
florfenicol. The MIC results of the selected B. bronchiseptica isolates of the 30 examined farms 
corresponded with the results of Farm 1 and 2 in Publication I. The macrorestriction analysis 




differed in their MIC values in only +/- one dilution step, we claim that the MIC testing for only 
one B. bronchiseptica clone within a pig herd and time point is sufficient. However, as already 
indicated for S. suis, closely related isolates differed in their MIC ranges of some antimicrobial 
agents, such as SXT (data not shown). 
The tetracycline MIC values of B. bronchiseptica of Farms 1 and 2 (Publication I) 
coincide with the tetracycline MIC90 of 0.5 mg/L (n=20) of B. bronchiseptica in all farms 
screened in this study (unpublished data Table 2). Moreover, this tetracycline MIC90 value is 
lower than the MIC90 values seen in the GERM-Vet and VetPath studies, both 2 mg/L [6, 65]. 
Doxycycline MIC90 was 0.25 mg/L (n=20) in the VASIB study (unpublished data Table 2). We 
assume a broad tetracycline and doxycycline susceptibility among our isolates. Other studies 
examined B. bronchiseptica isolates with much higher MICs of at least 64 mg/L and detected 
the tetracycline resistance genes tet(A) or tet(C) [92, 93]. We did not test for these genes, since 
the tetracycline MICs of our isolates were too low to be indicative for the presence of a tet 
gene. 
B. bronchiseptica exhibit β-lactam resistance due to the production of a species-specific 
β-lactamase as well as reduced outer membrane permeability. The lower amoxicillin/clavulanic 
acid MIC90 of 4/2 mg/L (n=20, unpublished data Table 2) of B. bronchiseptica correlates with 
the fact, that the species-specific β-lactamase plays an important role in resistance and is 
inhibited by clavulanic acid [89]. Agents without a β-lactamase inhibitor like ampicillin, penicillin 
or ceftiofur have no effect on B. bronchiseptica as shown by the comparatively high MIC values 
in Publication I and in the unpublished data Table 2. Furthermore, the ampicillin MIC values 
are indicated as resistant according to CLSI breakpoints (unpublished data Table 2). The high 
β-lactam MIC values were confirmed in the GERM-Vet and VetPath studies [6, 65]. In 
summary, the use of β-lactams for the control of B.  bronchiseptica infections without 
lactamase inhibitors should be avoided. Nevertheless, β-lactams, especially amoxicillin, are 
besides doxycycline the most frequently prescribed antimicrobials in this study and are 
indicated as frequently used antimicrobials in other surveys [1, 2, 15]. However, amoxicillin 
and even amoxicillin/clavulanic acid had no effect on B.  bronchiseptica, which was verified in 
Farms 1 and 2, where B. bronchiseptica was still detected at the last day of antimicrobial 
treatment with amoxicillin or amoxicillin/clavulanic acid. Furthermore, the extensive use of β-
lactams may promote the development of β-lactam resistance in other former highly β-lactam 
susceptible bacteria such as S. suis (Publication I and III). However, even though 
B.  bronchiseptica was verified after the antimicrobial treatment, the herd-health of Farms 1 





The B. bronchiseptica isolates of the VASIB study exhibited florfenicol MICs that 
classified them as susceptible (≤2 mg/L) or intermediate (4 mg/L, unpublished data Table 2). 
This is in accordance with the florfenicol MICs observed in the studies of VetPath, Priebe and 
Schwarz (2003) or Kadlec et al. (2004) and excludes the presence of an acquired resistance 
gene coding for florfenicol resistance. B. bronchiseptica isolates that harbor floR exhibit higher 
florfenicol MICs of ≥8 mg/L [95]. 
Tiamulin MIC values of B. bronchiseptica are quite high with ≥128 mg/L (Publication I, 
unpublished data Table 2). We assume no bacteriostatic effect on B. bronchiseptica, since 
their cell wall might confer a reduced antimicrobial influx. 
 
3.6 Antimicrobial susceptibility of P. multocida 
P. multocida isolates with different PFGE patterns were present at every sampling in 
Farm 2 (Publication I). Sometimes up to two different P. multocida isolates per time point were 
detected on a single farm (Figure S5). The MIC values of P. multocida isolates of Farms 1 and 
2 in Publication I give a good overview on the MIC profiles of P. multocida detected in the 
farms of the VASIB study. Hence, we suggest that an antibiogram for one representative 
isolate per sampling time point and farm may be sufficient. A second antibiogram should be 
performed when a genetically different P. multocida isolate is expected due to differing 
phenotypic characteristics. 
Most P. multocida isolates were susceptible to tetracyclines, but some exhibited MIC 
values that classified them as intermediate or resistant as already indicated in Publication I 
[91]. The tetracycline MIC90 of selected P. multocida isolates (n=39) was 1 mg/L (unpublished 
data Table 3) in the VASIB study. The highest MIC that classified P. multocida as tetracycline-
resistant in the present study was 2 mg/L (n=3). The isolates of the VetPath study had a MIC90 
of 2 mg/L [65]. Overall, we assume the presence of multi-drug efflux pumps, since the most 
common acquired tetracycline resistance gene tet(H) was not detected in the resistant 
P.  multocida isolates of this study [127, 128]. Further, the detected MIC values of 1 mg/L (n=9) 
and 2 mg/L (n=3) indicate the absence of a tetracycline resistance gene, which mediates 
distinctly higher MICs of at least 32 mg/L [130]. No CLSI breakpoints which allow a 
classification of the doxycycline susceptibility/resistance of P. multocida are available [91]. In 
the GERM-Vet study, a doxycycline MIC90 of 0.5 mg/L was determined for P. multocida from 
weaners [6]. The same doxycycline MIC90 was identified in the VASIB study (unpublished data 
Table 3). Doxycycline MIC values were up to one or two dilution steps lower than the 
tetracycline values (unpublished data Table 3). Thus, a slightly better effect of doxycycline on 




The P. multocida isolates revealed a high susceptibility to β-lactams according to CLSI 
breakpoints [91]. The penicillin MIC90 of 0.25 mg/L in GERM-Vet correspond to the MIC90 of 
0.12 mg/L (n=39, unpublished data Table 3) in the VASIB study [6]. Ampicillin and 
amoxicillin/clavulanic acid MIC90 values of the VASIB study were 0.25 mg/L and 0.25/0.12 mg/L 
(unpublished data Table 3), respectively. The VetPath study showed partly higher MIC90 values 
of 0.5 mg/L for amoxicillin and 0.5/0.25 mg/L for amoxicillin/clavulanic acid [65]. The examined 
pigs in our study were both, apparently healthy and diseased, whereas the VetPath and 
GERM-Vet studies exclusively investigated isolates from diseased pigs and examined a higher 
number of isolates (n≥150) [6, 65]. Nevertheless, the MIC results of the VASIB study as well 
as other studies like VetPath or GERM-Vet revealed a broad β-lactam susceptibility of 
P.  multocida and β-lactam usage during a single infection with P. multocida is supposed to be 
an effective therapeutic option. 
The florfenicol MIC90 of P. multocida in the VASIB study was 0.5 mg/L (n=39) and the 
isolates were classified as susceptible (unpublished data Table 3) [91]. The GERM-Vet and 
VetPath projects obtained also MIC90 values that indicate P. multocida as susceptible to 
florfenicol and give no presumption on the presence of florfenicol resistance genes. Since 
florfenicol formulations are approved for the treatment of infections caused by 
A.  pleuropneumoniae and P. multocida, florfenicol represents a favorable option to treat 
respiratory tract infections caused by P.  multocida. 
The tiamulin MICs in this study ranged from 4 mg/L to 32 mg/L with a MIC90 of 32 mg/L 
(n=39, unpublished data Table 3), but no CLSI breakpoints are available [91]. Furthermore, 
tiamulin formulations are only approved for gastrointestinal tract infections as well as 
respiratory tract infections with Mycoplasma spp. or A. pleuropneumoniae in pigs [68]. A 
treatment of respiratory tract infections caused by P. multocida, but also by S. suis as well as 
B.  bronchiseptica, with tiamulin is not recommended, since the respective bacteria exhibit 
higher MICs to tiamulin and a tiamulin off-label use would be necessary to treat those 
infections. 
Next to β-lactams, tetracyclines and polypeptide antibiotics, sulfonamides are also 
frequently prescribed antimicrobials in veterinary medicine [1, 2, 15]. In therapy, sulfonamides 
are commonly used in combination with trimethoprim to take advantage of their antimicrobial 
synergistic effects and reduced adverse drug reactions [138]. SXT is approved especially for 
primary and secondary gastrointestinal and respiratory tract infections with SXT-susceptible 
pathogens [68]. Publication II describes the occurrence of P. multocida isolates from three 
different farms with reduced SXT susceptibility. CLSI breakpoints of SXT susceptibility for 
P.  multocida are not available [91]. However, with regard to the common membership of 




breakpoints of H.  influenzae were used to deduce the SXT susceptibility of P. multocida. 
According to that, isolates with SXT MICs of ≥4/76 mg/L were classified as resistant [65]. The 
SXT MIC90 of the P.  multocida isolates in the VASIB study was 0.25/4.75 mg/L (n=39, data 
not shown). Nevertheless, isolates with SXT resistance were identified in three farms as 
described in Publication II. The 152 P.  multocida isolates of the VetPath project had a SXT 
MIC90 value of 0.5/9.5 mg/L and the isolates of the GERM-Vet study 16/304 mg/L (n=150) [6, 
65]. Further examinations of the SXT-resistant P. multocida in the VASIB study revealed a 
resistance plasmid pIMT41689_PM of 6 kb in all of these isolates (n=9). The small plasmid 
size is in accordance with other resistance plasmids of the family Pasteurellaceae [135]. 
Further examinations of the SXT-resistant isolates from the three different farms revealed their 
close relatedness, since they exhibited macrorestriction patterns with an identity of 100 % on 
farm level as well as 92.4 % and 94.7 % between the farms (Publication II). Moreover, the 
isolates of the three farms were classified as serotype A and ST13. Serotype A and ST13 are 
frequently associated with porcine bronchopneumonia [101, 167, 173]. These facts may 
indicate that the SXT-resistant isolates have a common ancestor and belong to the same clonal 
lineage. The structure of the 6 kb SXT resistance plasmid of P. multocida is described in 
Publication II. The trimethoprim resistance gene dfrA14 belongs to the dfrA gene family and 
encodes the 157 amino acid large, trimethoprim-insensitive DHFR, which is quite common on 
mobile genetic elements of Gram-negatives [138]. The dfrA14 gene is detected in P. multocida 
for the first time in the VASIB study. However, dfrA14 integrates quite commonly at a 
secondary site within the streptomycin resistance gene strA, which was already identified in 
other Gram-negatives, including Enterobacteriaceae and Pasteurellaceae [174, 175]. 
Furthermore, the region between sul2 and strA also seems to be associated with 
recombination events, as detected on plasmids or chromosomal DNA of Pasteurella 
aerogenes, Mannheimia varigena and Mannheimia sp. with the combination of sul2-catA3-
strA, or P. multocida with sul2-tetR-tet(H)-strA-strB [139, 141]. The insertion of dfrA14 into strA 
leads to the truncation and functional inactivity of strA. Furthermore, the also plasmid located 
strB gene exhibited a mutation that resulted in a stop codon already after 237 amino acids 
instead of 278 amino acids. The insertion and mutation resulted in dysfunctional streptomycin 
resistance proteins as verified by streptomycin MICs of 4 - 8 mg/L of the SXT-resistant isolates 
(data not shown) in this study. In contrast, intact streptomycin resistance genes confer much 
higher MICs of ≥64 mg/L [129]. The sul2 gene encodes a sulfonamide-insensitive DHPS that 
is frequently linked to strA-strB within members of the Pasteurellaceae family [135]. 
Furthermore, the genes mobA, mobB and mobC were located on plasmid pIMT41689_PM 
(Publication II). These genes encode proteins for the relaxosome formation during 
mobilization. A similar plasmid pM3224T with an identity to pIMT41689_PM of 99.9 % was 




suggest the presence of a conjugative element, which would enable a plasmid exchange 
between P. multocida and A. pleuropneumoniae within their common habitat of the porcine 
respiratory tract. It is rather unlikely that two so closely related plasmids have developed 
independent from each other. 
 
3.7 Concluding remarks 
The respiratory tract of pigs is usually colonized by a mixed flora of various bacteria with 
different antimicrobial susceptibilities. In this thesis, we focused on the relatedness and 
antimicrobial susceptibilities of S. suis, B. bronchiseptica and P. multocida. However, 
H.  parasuis, A. pleuropneumoniae or M. hyorhinis may also colonize the respiratory tract and 
need to be monitored for their antimicrobial susceptibilities, too. In this project, most porcine 
herds as well as the examined individual animals within those herds revealed mild respiratory 
tract symptoms. In addition, most pigs improved their respiratory fitness after the antimicrobial 
treatment, despite the presence of some isolates with a reduced susceptibility or resistance to 
the prescribed antibiotics. This may indicate their marginal role in causing respiratory 
symptoms. Other bacteria or viruses that colonize the respiratory tract may have caused the 
infection. Nevertheless, antimicrobial treatment results in a selection pressure on different 
bacterial species, which may either cause diseases or are present as commensal flora. Under 
a selective pressure, commensals, facultative and obligate pathogens can acquire resistance 
genes. The antimicrobial resistance profiles of the aforementioned pathogens were determined 
in each farm. However, the presented analyses revealed no acquisition of new antimicrobial 
resistance genes immediately after the antimicrobial therapy. Moreover, the examined 
pathogens differed in their susceptibility to the prescribed antimicrobials, except for florfenicol. 
This may indicate that florfenicol is an effective alternative to treat respiratory tract infections 
caused by S. suis, P. multocida and B. bronchiseptica. However, florfenicol is only approved 
for porcine respiratory tract infections caused by A. pleuropneumoniae and P.  multocida and 
an off-label use in some other indications would be necessary. Macrorestriction analyses 
revealed a large diversity of PFGE patterns of S. suis accompanied by variable susceptibility 
patterns of the corresponding isolates. In contrast, a limited diversity of PFGE patterns was 
observed for B. bronchiseptica and accordingly, the MICs of the respective isolates were also 
rather similar. The P. multocida isolates showed a genetic relatedness to some extent but were 
not as diverse as the S. suis isolates. Nevertheless, the MICs of the different P. multocida 
isolates had mostly a narrow range of distribution. Finally, one antibiogram for 
B.  bronchiseptica, up to two for morphological different P. multocida and at least antibiograms 




recommended for diagnostic laboratories in order to get a representative overview of the 






Streptococcus suis is a Gram-positive bacterium and a commensal colonizing the 
porcine respiratory tract. However, some serotypes have a higher virulence and can cause 
pneumonia, meningitis, septicaemia, arthritis, endocarditis, polyserositis or abortion in pigs. 
Bordetella bronchiseptica and Pasteurella multocida are Gram-negative bacteria that can 
cause bronchopneumonia or atrophic rhinitis. Bacterial infections of the porcine respiratory 
tract are commonly treated with antimicrobials. 
In this thesis, bronchoalveolar lavage fluid samples (BALFs) of weaners of four to ten 
weeks of age and originating from 30 farrow-to-finish farms were investigated for the 
aforementioned pathogens. Furthermore, the influence of antimicrobial treatment during 
respiratory tract infection on such pathogens within a one-year period was monitored. The 
genetic relatedness of selected S. suis, B. bronchiseptica and P. multocida isolates on farm 
level and between different farms was investigated by macrorestriction with subsequent 
pulsed-field gel electrophoresis (PFGE). In addition, the antimicrobial susceptibility and 
resistance mechanisms of the pathogens were determined. However, a valid recommendation 
to the susceptibility of the pathogens to all examined antibiotics is sometimes difficult, since 
CLSI approved breakpoints are not available for all tested antimicrobial agents. 
This study revealed a great diversity of PFGE patterns among S. suis isolates. Single 
pigs can harbor S. suis isolates with completely different macrorestriction patterns, which also 
differ in their antimicrobial susceptibilities. B. bronchiseptica showed a greater homogeneity in 
their PFGE patterns and P. multocida displayed related and different PFGE patterns. One or 
two closely related B. bronchiseptica isolates with quite similar minimal inhibitory 
concentrations (MICs) existed over a one-year period within one farm. One or two P. multocida 
isolates with different PFGE patterns can exist on one farm at a certain time point, nevertheless 
most P.  multocida isolates had similar MICs. Antimicrobial agents were prescribed 24 times 
for five to seven days in the farms of this project. Doxycycline was most frequently prescribed 
(n=14 times) in this study, followed by amoxicillin (n=8), amoxicillin/clavulanic acid (n=1) and 
tiamulin/florfenicol (n=1). 
S. suis isolates were frequently tetracycline-resistant, since they harbored resistance 
genes such as tet(O), tet(M), tet(L) or tet(W). S. suis exhibited higher MICs to tiamulin, was 
susceptible to florfenicol and to aminopenicillins alone and in combination with clavulanic acid. 
However, individual S. suis isolates showed distinctly higher MICs to penicillin. Therefore, 
three S. suis isolates, which were susceptible, intermediate or resistant to penicillin were 
subjected to whole genome sequencing. The analyses of the whole genome sequences 




penicillin-resistant isolate had the most amino acid alterations in PBP2x, PBP2b and PBP2a, 
whereas the penicillin-intermediate isolate had the most amino acid substitutions only in 
PBP2x and PBP2b compared to the penicillin-susceptible isolate. However, none of the 
isolates exhibited amino acid alterations in the conserved motifs, which form the catalytic 
centre of the PBPs and interact with penicillin. 
Tetracyclines may have bacteriostatic effects on B. bronchiseptica, since these bacteria 
exhibit low doxycycline and tetracycline MIC90 values of 0.25 mg/L and 0.5 mg/L, respectively. 
The B.  bronchiseptica isolates showed an overall reduced susceptibility to β-lactams except 
for amoxicillin/clavulanic acid. B. bronchiseptica isolates had a tiamulin MIC90 of ≥128 mg/L 
and were either susceptible or intermediate towards florfenicol. 
The P. multocida isolates were overall β-lactam- and florfenicol-susceptible. Some 
isolates showed tetracycline MICs of 1 mg/L (n=9) and 2 mg/L (n=3) that classified the 
respective isolates as intermediate and resistant, respectively. The tiamulin MIC90 was 
32  mg/L. Regardless of the antimicrobial treatment on the farms, 
trimethoprim/sulfamethoxazole (SXT)-resistant P. multocida isolates were detected on three 
different farrow-to-finish farms. A closer examination of these isolates revealed their close 
genetic relatedness and the existence of a dfrA14-carrying, 6 kb plasmid. The dfrA14 gene 
mediates trimethoprim resistance and was detected in P. multocida for the first time. However, 
a similar plasmid with a nucleotide sequence identity of 99.9 % to that of P. multocida was 
already identified in Actinobacillus pleuropneumoniae. Hence, we suspect that a plasmid 
exchange of the pathogens within the common habitat of the porcine respiratory tract has taken 
place in the past. 
The MIC testing revealed a broad susceptibility of S. suis and P. multocida to florfenicol 
as well as an intermediate susceptibility of B. bronchiseptica, which might identify florfenicol 
as an effective therapeutic alternative to tetracyclines or β-lactams. Besides, the frequent use 
of β-lactams, tetracyclines and sulfonamides in veterinary medicine increases the selection 
pressure on certain pathogens as shown in this thesis. Tetracycline resistance genes seems 
to become conserved in the streptococcal genome due to the frequent use of doxycycline. 
Former fully β-lactam susceptible isolates, such as S. suis, accumulate amino acid alterations 
in their PBPs, which mediate a lower affinity to penicillin. The development of a SXT resistance 
plasmid and its presence in already two members of the family Pasteurellaceae, demonstrates 





Genetische Verwandtschaft und antimikrobielle Empfindlichkeit der porzinen 
Atemwegsinfektionserreger Streptococcus suis, Bordetella bronchiseptica und 
Pasteurella multocida 
Streptococcus suis ist ein Gram-positives Bakterium und besiedelt den Respirationstrakt 
von Schweinen als Kommensale. Einige Serotypen haben jedoch eine höhere Virulenz, durch 
welche Pneumonien, Meningitis, Septikämien, Arthritis, Endokarditis, Polyserositis oder Abort 
bei Schweinen ausgelöst werden können. Bordetella bronchiseptica und Pasteurella multocida 
sind Gram-negative Bakterien, welche Bronchopneumonien oder Rhinitis atrophicans 
auslösen können. Bakterielle Infektionen des Respirationstrakts von Schweinen werden 
gewöhnlich mit Antibiotika behandelt. 
In dieser Arbeit wurden bronchoalveoläre Lavageflüssigkeiten (BALF) von vier bis zehn 
Wochen alten Absetzferkeln aus 30 Ferkelerzeugerbetrieben auf die vorab genannten 
Pathogene hin untersucht sowie die antimikrobielle Behandlung von Atemwegserkrankungen 
innerhalb eines Jahres erfasst. Die genetische Verwandtschaft ausgewählter S. suis, 
B.  bronchiseptica und P. multocida Isolate wurde auf Betriebsebene sowie zwischen 
verschiedenen Betrieben mit Hilfe der Makrorestriktionsanalyse und anschließender Pulsfeld-
Gelelektrophorese (PFGE) analysiert. Zusätzlich wurde die antimikrobielle Empfindlichkeit der 
Pathogene sowie deren Resistenzmechanismen untersucht. Die Bewertung der 
Empfindlichkeit einiger Pathogene gestaltete sich teilweise schwierig, da nicht für alle 
getesteten Antibiotika seitens CLSI anerkannte Grenzwerte vorhanden sind. 
Diese Studie zeigt eine große genetische Diversität zwischen den untersuchten S. suis 
Isolaten. Einzelne Schweine können S. suis Isolate mit unterschiedlichen 
Makrorestriktionsmustern und verschiedenen antimikrobiellen Empfindlichkeiten tragen. 
B.  bronchiseptica zeigte eine größere genetische Homogenität hinsichtlich der 
Makrorestriktionsmuster, wohingegen P. multocida eine etwas breitere Verwandtschaft der 
Isolate aufweist. Pro Betrieb konnten in einem Zeitraum von einem Jahr ein oder zwei eng 
verwandte B. bronchiseptica Isolate mit ähnlichen minimalen Hemmstoffkonzentrationen 
(MHKs) nachgewiesen werden. Im Vergleich dazu, konnten mitunter zwei P. multocida Isolate 
mit unterschiedlichen Makrorestriktionsmustern im gleichen Betrieb zu einem bestimmten 
Zeitpunkt existieren, welche jedoch ähnliche MHK Werte aufweisen. Die antimikrobielle 
Behandlung auf den Betrieben dauerte fünf bis sieben Tage. Insgesamt wurde auf den Farmen 
24-mal ein Antibiotikum angewendet. Doxycyclin war mit 14 Anwendungen das am häufigsten 
verwendete Antibiotikum in dieser Studie, gefolgt von Amoxicillin (8 Anwendungen) sowie 




S. suis Isolate waren meist resistent gegenüber Tetrazyklinen, da sie Resistenzgene wie 
z.B. tet(O), tet(M), tet(L) oder tet(W) trugen. S. suis zeigte erhöhte MHK Werte gegenüber 
Tiamulin, war jedoch empfindlich gegenüber Aminopenicillinen und deren Kombination mit 
Clavulansäure. Jedoch zeigten einige S. suis Isolate auch deutlich höhere Penicillin MHK-
Werte. Aus diesem Grund wurden drei Isolate, welche empfindlich, intermediär und resistent 
gegenüber Penicillin waren, ausgewählt und einer Gesamtgenomsequenzierung unterzogen. 
Die Analyse der Gesamtgenomsequenzen ergab für die drei Isolate jeweils fünf Gene, die für 
Penicillin-bindende Proteine (PBPs) kodierten. Im Vergleich zu dem Penicillin-sensiblen Isolat 
wies das Penicillin-resistente Isolat die meisten Aminosäureänderungen in PBP2x, PBP2b und 
PBP2a auf, wohingegen das Penicillin-intermediäre Isolat die meisten Aminosäureänderungen 
in PBP2x und PBP2b aufwies. Keines der Isolate zeigte Aminosäureveränderungen in den 
konservierten Sequenzmotiven, welche das katalytische Zentrum der PBPs bilden und mit 
Penicillin interagieren. 
Die untersuchten B. bronchiseptica Isolate zeigten niedrige Doxycyclin und Tetrazyklin 
MHK90 Werte mit jeweils 0.25 mg/L und 0.5 mg/L, welche einen bakteriostatischen Effekt 
haben könnten. Die B. bronchiseptica Isolate besitzen eine umfassende β-Laktam Resistenz, 
ausgenommen gegen die Kombination von Amoxicillin/Clavulansäure. In dieser Studie hatten 
die B. bronchiseptica Isolate einen Tiamulin MHK90 von 128 mg/L und zeigten MHK-Werte, die 
sie als empfindlich oder intermediär gegenüber Florfenicol klassifizieren. 
P. multocida war empfindlich gegenüber β-Laktamen und Florfenicol. Einzelne 
P.  multocida Isolate zeigten mit 1 mg/L (n=9) und 2 mg/L (n=3) Tetrazyklin MHK Werte, die 
sie als intermediär bzw. resistent klassifizieren. Der Tiamulin MHK90 der untersuchten Isolate 
lag bei 32 mg/L. Unabhängig von den Antibiotikabehandlungen in den Betrieben wurden 
Trimethoprim/Sulfamethoxazol (SXT)-resistente P. multocida Isolate in drei verschiedenen 
Ferkelerzeugerbetrieben detektiert. Eine genauere Untersuchung dieser Isolate ergab eine 
enge genetische Verwandtschaft zwischen diesen Isolaten und das Vorhandensein eines 6 kb 
großen Plasmides, welches die Gene sul2 und dfrA14 trug. Das dfrA14 Gen vermittelt 
Resistenz gegenüber Trimethoprim und wurde in dieser Studie zum ersten Mal bei 
P.  multocida nachgewiesen. Ein ähnliches Plasmid mit einer Sequenzübereinstimmung von 
99.9 % wurde bereits bei Actinobacillus pleuropneumoniae identifiziert. Man könnte daher 
einen Plasmidaustausch zwischen den beiden Bakterienspezies in ihrem gemeinsamen 
Habitat, dem Respirationstrakt des Schweins, in der Vergangenheit annehmen. 
Unsere Untersuchungen verdeutlichten, dass S. suis und P. multocida eine hohe 
Empfindlichkeit gegenüber Florfenicol besitzen, während B. bronchiseptica auch intermediäre 
MHK Werte aufweist. Daher kann Florfenicol als eine wirkungsvolle Therapiealternative zu 




β-Laktamen, Tetrazyklinen und Sulfonamiden in der Veterinärmedizin zu einem erhöhten 
Selektionsdruck gegenüber einigen Pathogenen, wie in dieser Studie gezeigt wurde. Gene, 
welche Tetrazyklinresistenz vermitteln, scheinen durch den häufigen Therapieeinsatz von 
Doxycyclin bereits im Streptokokkengenom konserviert zu sein. Zudem weisen Isolate, wie 
z.B. S. suis, die zuvor vollständig empfindlich gegenüber Penicillin waren, eine Ansammlung 
von Aminosäureveränderungen in ihren PBPs auf. Diese Veränderungen können zu einer 
geringeren Affinität der Isolate gegenüber Penicillinen führen. Die Entstehung eines SXT- 
Resistenzgene-tragenden Plasmids sowie dessen bereits vorliegende Existenz in zwei 
Mitgliedern der Familie Pasteurellaceae verdeutlicht die mögliche weitere Verbreitung solcher 






1. BMEL. Bundeministerium für Ernährung und Landwirtschaft, Lagebild zur 
Antibiotikaresistenz im Bereich Tierhaltung und Lebensmittelkette, AG 
Antibiotikaresistenz. 2018. 
2. BVL. Bundesamt für Verbraucherschutz und Lebensmittelsicherheit, Vergleich der 
Abgabemengen der Wirkstoffklassen 2011 bis 2017. 2018. 
3. BVL. Bundesamt für Verbraucherschutz und Lebensmittelsicherheit, Paul-Ehrlich-
Gesellschaft für Chemotherapie e.V. GERMAP 2008 - Bericht über den 
Antibiotikaverbrauch und die Verbreitung von Antibiotikaresistenzen in der Human- und 
Veterinärmedizin in Deutschland. Antiinfective Intelligence. 2008. 
4. BVL. Bundesamt für Verbraucherschutz und Lebensmittelsicherheit, Paul-Ehrlich-
Gesellschaft für Chemotherapie e.V. GERMAP 2010 - Bericht über den 
Antibiotikaverbrauch und die Verbreitung von Antibiotikaresistenzen in der Human- und 
Veterinärmedizin in Deutschland Antiinfectives Intelligence. 2011. 
5. BVL. Bundesamt für Verbraucherschutz und Lebensmittelsicherheit, Paul-Ehrlich-
Gesellschaft für Chemotherapie e.V. GERMAP 2012 - Bericht über den 
Antibiotikaverbrauch und die Verbreitung von Antibiotikaresistenzen in der Human- und 
Veterinärmedizin in Deutschland. Antiinfectives Intelligence. 2014. 
6. BVL. Bundesamt für Verbraucherschutz und Lebensmittelsicherheit, Paul-Ehrlich-
Gesellschaft für Chemotherapie e.V. GERMAP 2015 - Bericht über den 
Antibiotikaverbrauch und die Verbreitung von Antibiotikaresistenzen in der Human- und 
Veterinärmedizin in Deutschland. Antiinfectives Intelligence. 2016. 
7. Dahinten G, Littmann E. Schweinezucht und -vermarktung in Die Landwirtschaft - 
Landwirtschaftliche Tierhaltung, Littmann E, Hammerl G, Adam F, Editors. 2016, BLV 
Buchverlag GmbH & Co.KG: München. p. 551-599. 
8. Jais C, Stalljohann G, Schäffler M, Wolfrum W. Schweinehaltung und -fütterung in Die 
Landwirtschaft - Landwirtschaftliche Tierhaltung, Littmann E, Hammerl G, Adam F, 
Editors. 2016, BLV Buchverlag GmbH & Co.KG: München. p. 551-599. 
9. Krieter J. Schweinehaltung und -fütterung in Nutztierhaltung und -hygiene, Hoy S, Gauly 
M, Krieter J, Editors. 2016, Verlag Eugen Ulmer KG: Stuttgart. p. 73-145. 
10. Kayser FH, Böttger EC. Epidemiologie und Hygiene in Taschenlehrbuch Medizinische 
Mikrobiologie, Kayser FH, Böttger EC, Deplazes P, Haller O, Roers A, Editors. 2014, 
Thieme. p. 73-99. 
11. USFDA. US Food and Drug Administration, 2017 Summary report on antimicrobials sold 
or distributed for use in food-producing animals. 2018. 
12. Tenover FC, Arbeit RD, Goering RV, Mickelsen PA, Murray BE, Persing DH, 
Swaminathan B. Interpreting chromosomal DNA restriction patterns produced by pulsed-
field gel electrophoresis: criteria for bacterial strain typing. J Clin Microbiol. 1995. 33: p. 
2233-2239. 
13. Ørskov F, Ørskov I. From the national institutes of health. Summary of a workshop on 
the clone concept in the epidemiology, taxonomy, and evolution of the 




14. Grosse Beilage E, Nathues H, Grummer B, Hartung J, Kamphues J, Kietzmann M, 
Rohde J, Spindler B, Weissenböck H. Diagnostik, Prophylaxe und Therapie von 
Atemwegserkrankungen in Schweinebeständen in Diagnostik und 
Gesundheitsmanagement im Schweinebestand, Grosse Beilage E, Wendt M, Editors. 
2013, Eugen Ulmer KG: Stuttgart. p. 200-270. 
15. van Rennings L, von Münchhausen C, Ottilie H, Hartmann M, Merle R, Honscha W, 
Käsbohrer A, Kreienbrock L. Cross-sectional study on antibiotic usage in pigs in 
Germany. PLoS ONE. 2015. 10: p. e0119114. 
16. Spellerberg B, Brandt C. Gram positive cocci: Streptococcus in Manual of clinical 
microbiology, Jorgensen JH, Pfaller MA, Carroll KC, Funke G, Landry ML, Richter SS, 
Warnock DW, Editors. 2015, ASM: Washington DC. p. 383-402. 
17. Lancefield RC. A serological differentiation of human and other groups of hemolytic 
streptococci. J Exp Med. 1933. 57: p. 571. 
18. Brousseau R, Hill JE, Préfontaine G, Goh SH, Harel J, Hemmingsen SM. Streptococcus 
suis serotypes characterized by analysis of chaperonin 60 gene sequences. Appl 
Environ Microbiol. 2001. 67: p. 4828-4833. 
19. Staats JJ, Feder I, Okwumabua O, Chengappa MM. Streptococcus suis: past and 
present. Vet Res Commun. 1997. 21: p. 381-407. 
20. Tien LHT, Nishibori T, Nishitani Y, Nomoto R, Osawa R. Reappraisal of the taxonomy of 
Streptococcus suis serotypes 20, 22, 26, and 33 based on DNA-DNA homology and 
sodA and recN phylogenies. Vet Microbiol. 2013. 162: p. 842-849. 
21. Hill JE, Gottschalk M, Brousseau R, Harel J, Hemmingsen SM, Goh SH. Biochemical 
analysis, cpn60 and 16S rDNA sequence data indicate that Streptococcus suis serotypes 
32 and 34, isolated from pigs, are Streptococcus orisratti. Vet Microbiol. 2005. 107: p. 
63-69. 
22. King SJ, Leigh JA, Heath PJ, Luque I, Tarradas C, Dowson CG, Whatmore AM. 
Development of a multilocus sequence typing scheme for the pig pathogen 
Streptococcus suis: identification of virulent clones and potential capsular serotype 
exchange. J Clin Microbiol. 2002. 40: p. 3671-3680. 
23. Berthelot-Hérault F, Gottschalk M, Labbé A, Cariolet R, Kobisch M. Experimental 
airborne transmission of Streptococcus suis capsular type 2 in pigs. Vet Microbiol. 2001. 
82: p. 69-80. 
24. Dee SA, Corey MM. The survival of Streptococcus suis on farm and veterinary 
equipment. J Swine Health Prod. 1993. 1: p. 17-20. 
25. Wisselink HJ, Smith HE, Stockhofe-Zurwieden N, Peperkamp K, Vecht U. Distribution of 
capsular types and production of muramidase-released protein (MRP) and extracellular 
factor (EF) of Streptococcus suis strains isolated from diseased pigs in seven European 
countries. Vet Microbiol. 2000. 74: p. 237-248. 
26. Smith HE, Damman M, van der Velde J, Wagenaar F, Wisselink HJ, Stockhofe-
Zurwieden N, Smits MA. Identification and characterization of the cps locus of 
Streptococcus suis serotype 2: the capsule protects against phagocytosis and is an 




27. Allen AG, Lindsay H, Seilly D, Bolitho S, Peters SE, Maskell DJ. Identification and 
characterisation of hyaluronate lyase from Streptococcus suis. Microb Pathog. 2004. 36: 
p. 327-235. 
28. Vecht U, Wisselink HJ, van Dijk JE, Smith HE. Virulence of Streptococcus suis type 2 
strains in newborn germfree pigs depends on phenotype. Infect Immun. 1992. 60: p. 550-
556. 
29. Smith HE, Vecht U, Gielkens AL, Smits MA. Cloning and nucleotide sequence of the 
gene encoding the 136-kilodalton surface protein (muramidase-released protein) of 
Streptococcus suis type 2. Infect Immun. 1992. 60: p. 2361. 
30. Smith HE, Reek FH, Vecht U, Gielkens AL, Smits MA. Repeats in an extracellular protein 
of weakly pathogenic strains of Streptococcus suis type 2 are absent in pathogenic 
strains. Infect Immun. 1993. 61: p. 3318-3326. 
31. Smith HE, Vecht U, Wisselink HJ, Stockhofe-Zurwieden N, Biermann Y, Smits MA. 
Mutants of Streptococcus suis types 1 and 2 impaired in expression of muramidase-
released protein and extracellular protein induce disease in newborn germfree pigs. 
Infect Immun. 1996. 64: p. 4409-4412. 
32. Jacobs AA, Loeffen PL, van den Berg AJ, Storm PK. Identification, purification, and 
characterization of a thiol-activated hemolysin (suilysin) of Streptococcus suis. Infect 
Immun. 1994. 62: p. 1742-1748. 
33. Gottschalk MG, Lacouture S, Dubreuil JD. Characterization of Streptococcus suis 
capsular type 2 haemolysin. Microbiology. 1995. 141: p. 189-195. 
34. Gottschalk M, Segura M, Xu J. Streptococcus suis infections in humans: the Chinese 
experience and the situation in North America. Anim Health Res Rev. 2007. 8: p. 29-45. 
35. Arends JP, Zanen HC. Meningitis caused by Streptococcus suis in humans. Rev Infect 
Dis. 1988. 10: p. 131-137. 
36. Devriese LA, Haesebrouck F, de Herdt P, Dom P, Ducatelle R, Desmidt M, Messier S, 
Higgins R. Streptococcus suis infections in birds. Avian Pathol. 1994. 23: p. 721-724. 
37. Wertheim HF, Nghia HD, Taylor W, Schultsz C. Streptococcus suis: an emerging human 
pathogen. Clin Infect Dis. 2009. 48: p. 617-625. 
38. van Duijkeren E, Schink AK, Roberts MC, Wang Y, Schwarz S. Mechanisms of bacterial 
resistance to antimicrobial agents. Microbiol Spectr. 2018. 6(1): 
doi:10.1128/microbiolspec.ARBA-0019-2017. 
39. Aarestrup FM, Schwarz S. Antimicrobial resistance in staphylococci and streptococci of 
animal origin in Antimicrobial resistance in bacteria of animal origin, Aarestrup FM, 
Editor. 2006, ASM: Washington DC. p. 187-212. 
40. Ubukata K, Nonoguchi R, Matsuhashi M, Konno M. Expression and inducibility in 
Staphylococcus aureus of the mecA gene, which encodes a methicillin-resistant S. 
aureus-specific penicillin-binding protein. J Bacteriol. 1989. 171: p. 2882-2885. 
41. Wilke MS, Lovering AL, Strynadka NCJ. β-Lactam antibiotic resistance: a current 




42. Cain D, Malouin F, Dargis M, Harel J, Gottschalk M. Alterations in penicillin-binding 
proteins in strains of Streptococcus suis possessing moderate and high levels of 
resistance to penicillin. FEMS Microbiol Lett. 1995. 130: p. 121-127. 
43. Hu P, Yang M, Zhang A, Wu J, Chen B, Hua Y, Yu J, Chen H, Xiao J, Jin M. Comparative 
genomics study of multi-drug-resistance mechanisms in the antibiotic-resistant 
Streptococcus suis R61 strain. PLoS One. 2011. 6: p. e24988. 
44. Ghuysen JM. Serine β-lactamases and penicillin-binding proteins. Annu Rev Microbiol. 
1991. 45: p. 37-67. 
45. Sauvage E, Kerff F, Terrak M, Ayala JA, Charlier P. The penicillin-binding proteins: 
structure and role in peptidoglycan biosynthesis. FEMS Microbiol Rev. 2008. 32: p. 234-
258. 
46. Hakenbeck R, Brückner R, Denapaite D, Maurer P. Molecular mechanisms of β-lactam 
resistance in Streptococcus pneumoniae. Future Microbiol. 2012. 7: p. 395-410. 
47. Dessen A, Mouz N, Gordon E, Hopkins J, Dideberg O. Crystal structure of PBP2x from 
a highly penicillin-resistant Streptococcus pneumoniae clinical isolate: a mosaic 
framework containing 83 mutations. J Biol Chem. 2001. 276: p. 45106-45112. 
48. Contreras-Martel C, Dahout-Gonzalez C, Martins Ados S, Kotnik M, Dessen A. PBP 
active site flexibility as the key mechanism for β-lactam resistance in pneumococci. J Mol 
Biol. 2009. 387: p. 899-909. 
49. Dale JW, Park SF. Gene transfer in Molecular genetics of bacteria, Dale JW, Park SF, 
Editors. 2010, Wiley. p. 165-188. 
50. Laible G, Spratt BG, Hakenbeck R. Interspecies recombinational events during the 
evolution of altered PBP 2x genes in penicillin-resistant clinical isolates of Streptococcus 
pneumoniae. Mol Microbiol. 1991. 5: p. 1993-2002. 
51. Dowson CG, Hutchison A, Brannigan JA, George RC, Hansman D, Linares J, Tomasz 
A, Smith JM, Spratt BG. Horizontal transfer of penicillin-binding protein genes in 
penicillin-resistant clinical isolates of Streptococcus pneumoniae. Proc Natl Acad Sci 
USA. 1989. 86: p. 8842-8846. 
52. Martin C, Sibold C, Hakenbeck R. Relatedness of penicillin-binding protein 1a genes 
from different clones of penicillin-resistant Streptococcus pneumoniae isolated in South 
Africa and Spain. EMBO J. 1992. 11: p. 3831-3836. 
53. Hakenbeck R, König A, Kern I, van der Linden M, Keck W, Billot-Klein D, Legrand R, 
Schoot B, Gutmann L. Acquisition of five high-Mr penicillin-binding protein variants during 
transfer of high-level β-lactam resistance from Streptococcus mitis to Streptococcus 
pneumoniae. J Bacteriol. 1998. 180: p. 1831-1840. 
54. Reichmann P, König A, Linares J, Alcaide F, Tenover FC, McDougal L, Swidsinski S, 
Hakenbeck R. A global gene pool for high-level cephalosporin resistance in commensal 
Streptococcus species and Streptococcus pneumoniae. J Infect Dis. 1997. 176: p. 1001-
1012. 
55. Contreras-Martel C, Job V, Di Guilmi AM, Vernet T, Dideberg O, Dessen A. Crystal 
structure of penicillin-binding protein 1a (PBP1a) reveals a mutational hotspot implicated 




56. Pagliero E, Chesnel L, Hopkins J, Croize J, Dideberg O, Vernet T, Di Guilmi AM. 
Biochemical characterization of Streptococcus pneumoniae penicillin-binding protein 2b 
and its implication in β-lactam resistance. Antimicrob Agents Chemother. 2004. 48: p. 
1848-1855. 
57. Contreras-Martel C, Dahout-Gonzalez C, Martins ADS, Kotnik M, Dessen A. PBP active 
site flexibility as the key mechanism for β-lactam resistance in pneumococci. J Mol Biol. 
2009. 387: p. 899-909. 
58. Smith AM, Klugman KP. Alterations in PBP 1A essential for high-level penicillin 
resistance in Streptococcus pneumoniae. Antimicrob Agents Chemother. 1998. 42: p. 
1329-1333. 
59. Munoz R, Dowson CG, Daniels M, Coffey TJ, Martin C, Hakenbeck R, Spratt BG. 
Genetics of resistance to third-generation cephalosporins in clinical isolates of 
Streptococcus pneumoniae. Mol Microbiol. 1992. 6: p. 2461-2465. 
60. Roberts MC. Update on acquired tetracycline resistance genes. FEMS Microbiol Lett. 
2005. 245: p. 195-203. 
61. Hoa NT, Chieu TTB, Nghia HDT, Mai NTH, Anh PH, Wolbers M, Baker S, Campbell JI, 
Chau NVV, Hien TT, Farrar J, Schultsz C. The antimicrobial resistance patterns and 
associated determinants in Streptococcus suis isolated from humans in southern 
Vietnam, 1997-2008. BMC Infect Dis. 2011. 11: p. 1-8. 
62. Palmieri C, Magi G, Mingoia M, Bagnarelli P, Ripa S, Varaldo PE, Facinelli B. 
Characterization of a Streptococcus suis tet(O/W/32/O)-carrying element transferable to 
major streptococcal pathogens. Antimicrob Agents Chemother. 2012. 56: p. 4697-4702. 
63. Palmieri C, Varaldo PE, Facinelli B. Streptococcus suis, an emerging drug-resistant 
animal and human pathogen. Front Microbiol. 2011. 2: p. 235. 
64. Gurung M, Tamang MD, Moon DC, Kim SR, Jeong JH, Jang GC, Jung SC, Park YH, 
Lim SK. Molecular basis of resistance to selected antimicrobial agents in the emerging 
zoonotic pathogen Streptococcus suis. J Clin Microbiol. 2015. 53: p. 2332-2336. 
65. El Garch F, de Jong A, Simjee S, Moyaert H, Klein U, Ludwig C, Marion H, Haag-
Diergarten S, Richard-Mazet A, Thomas V, Siegwart E. Monitoring of antimicrobial 
susceptibility of respiratory tract pathogens isolated from diseased cattle and pigs across 
Europe, 2009-2012: VetPath results. Vet Microbiol. 2016. 194: p. 11-22. 
66. Kehrenberg C, Mumme J, Wallmann J, Verspohl J, Tegeler R, Kuhn T, Schwarz S. 
Monitoring of florfenicol susceptibility among bovine and porcine respiratory tract 
pathogens collected in Germany during the years 2002 and 2003. J Antimicrob 
Chemother. 2004. 54: p. 572-574. 
67. Schwarz S, Kehrenberg C, Doublet B, Cloeckaert A. Molecular basis of bacterial 
resistance to chloramphenicol and florfenicol. FEMS Microbiol Rev. 2004. 28: p. 519-
542. 
68. VETIDATA. www.vetidata.de. 2018. 
69. Kehrenberg C, Schwarz S. fexA, a novel Staphylococcus lentus gene encoding 





70. Wang Y, Li D, Song L, Liu Y, He T, Liu H, Wu C, Schwarz S, Shen J. First report of the 
multiresistance gene cfr in Streptococcus suis. Antimicrob Agents Chemother. 2013. 57: 
p. 4061-4063. 
71. Long KS, Poehlsgaard J, Kehrenberg C, Schwarz S, Vester B. The cfr rRNA 
methyltransferase confers resistance to phenicols, lincosamides, oxazolidinones, 
pleuromutilins, and streptogramin A antibiotics. Antimicrob Agents Chemother. 2006. 50: 
p. 2500-2505. 
72. Takamatsu D, Osaki M, Sekizaki T. Chloramphenicol resistance transposable element 
TnSs1 of Streptococcus suis, a transposon flanked by IS6-family elements. Plasmid. 
2003. 49: p. 143-151. 
73. Roberts MC. Update on macrolide–lincosamide–streptogramin, ketolide, and 
oxazolidinone resistance genes. FEMS Microbiol Lett. 2008. 282: p. 147-159. 
74. Roberts MC, Sutcliffe J, Courvalin P, Jensen LB, Rood J, Seppala H. Nomenclature for 
macrolide and macrolide-lincosamide-streptogramin B resistance determinants. 
Antimicrob Agents Chemother. 1999. 43: p. 2823-2830. 
75. Goodnow RA. Biology of Bordetella bronchiseptica. Microbiol Rev. 1980. 44: p. 722-738. 
76. Sanden GN, Weyant RS. Genus III. Bordetella in Bergey's manual of systematic 
bacteriology, the Proteobacteria, part C the Alpha-, Beta-, Delta-, and 
Epsilonproteobacteria, Garrity GM, Brenner DJ, Krieg NR, Staley JT, Editors. 2005, 
Springer Verlag: New York. p. 662-671. 
77. Wirsing von König C-H, Riffelmann M, Coenye T. Gram negative bacteria: Bordetella 
and related genera in Manual of clinical microbiology, Jorgensen JH, Pfaller MA, Carroll 
KC, Funke G, Landry ML, Richter SS, Warnock DW, Editors. 2015, ASM: Washington 
DC. p. 838-850. 
78. Mattoo S, Cherry JD. Molecular pathogenesis, epidemiology, and clinical manifestations 
of respiratory infections due to Bordetella pertussis and other Bordetella subspecies. Clin 
Microbiol Rev. 2005. 18: p. 326-382. 
79. Melton AR, Weiss AA. Environmental regulation of expression of virulence determinants 
in Bordetella pertussis. J Bacteriol. 1989. 171: p. 6206-6212. 
80. Melton AR, Weiss AA. Characterization of environmental regulators of Bordetella 
pertussis. Infect Immun. 1993. 61: p. 807-815. 
81. Martinez de Tejada G, Miller JF, Cotter PA. Comparative analysis of the virulence control 
systems of Bordetella pertussis and Bordetella bronchiseptica. Mol Microbiol. 1996. 22: 
p. 895-908. 
82. Horiguchi Y, Nakai T, Kume K. Effects of Bordetella bronchiseptica dermonecrotic toxin 
on the structure and function of osteoblastic clone MC3T3-E1 cells. Infect Immun. 1991. 
59: p. 1112-1116. 
83. Gentry-Weeks CR, Cookson BT, Goldman WE, Rimler RB, Porter SB, Curtiss R, 3rd. 
Dermonecrotic toxin and tracheal cytotoxin, putative virulence factors of Bordetella 




84. Cotter PA, Miller JF. BvgAS-mediated signal transduction: analysis of phase-locked 
regulatory mutants of Bordetella bronchiseptica in a rabbit model. Infect Immun. 1994. 
62: p. 3381-3390. 
85. Akerley BJ, Monack DM, Falkow S, Miller JF. The bvgAS locus negatively controls 
motility and synthesis of flagella in Bordetella bronchiseptica. J Bacteriol. 1992. 174: p. 
980-990. 
86. Brockmeier SL, Lager KM. Experimental airborne transmission of porcine reproductive 
and respiratory syndrome virus and Bordetella bronchiseptica. Vet Microbiol. 2002. 89: 
p. 267-275. 
87. Brockmeier SL, Halbur PG, Thacker EL. Porcine respiratory disease complex in 
Polymicrobial diseases, Brogden KA, Guthmiller JM, Editors. 2002, ASM: Washington, 
DC. p. 231-258. 
88. Woolfrey BF, Moody JA. Human infections associated with Bordetella bronchiseptica. 
Clin Microbiol Rev. 1991. 4: p. 243-255. 
89. Lartigue M-F, Poirel L, Fortineau N, Nordmann P. Chromosome-borne class A BOR-1 β-
lactamase of Bordetella bronchiseptica and Bordetella parapertussis. Antimicrob Agents 
Chemother. 2005. 49: p. 2565-2567. 
90. Kadlec K, Wiegand I, Kehrenberg C, Schwarz S. Studies on the mechanisms of β-lactam 
resistance in Bordetella bronchiseptica. J Antimicrob Chemother. 2007. 59: p. 396-402. 
91. CLSI, Clinical and Laboratory Standards Institute - Performance standards for 
antimicrobial disk and dilution susceptibility tests for bacteria isolated from animals, in 
CLSI supplement VET01-S, Wayne, PA, USA. 2015. 
92. Speakman AJ, Binns SH, Osborn AM, Corkill JE, Kariuki S, Saunders JR, Dawson S, 
Gaskell RM, Hart CA. Characterization of antibiotic resistance plasmids from Bordetella 
bronchiseptica. J Antimicrob Chemother. 1997. 40: p. 811-816. 
93. Kadlec K, Kehrenberg C, Schwarz S. tet(A)-mediated tetracycline resistance in porcine 
Bordetella bronchiseptica isolates is based on plasmid-borne Tn1721 relics. J Antimicrob 
Chemother. 2006. 58: p. 225-227. 
94. Møller TSB, Overgaard M, Nielsen SS, Bortolaia V, Sommer MOA, Guardabassi L, Olsen 
JE. Relation between tetR and tetA expression in tetracycline resistant Escherichia coli. 
BMC Microbiol. 2016. 16: p. 1-8. 
95. Kadlec K, Kehrenberg C, Schwarz S. Efflux-mediated resistance to florfenicol and/or 
chloramphenicol in Bordetella bronchiseptica: identification of a novel chloramphenicol 
exporter. J Antimicrob Chemother. 2007. 59: p. 191-196. 
96. Kadlec K, Kehrenberg C, Schwarz S. Molecular basis of resistance to trimethoprim, 
chloramphenicol and sulphonamides in Bordetella bronchiseptica. J Antimicrob 
Chemother. 2005. 56: p. 485-490. 
97. Poole K. Multidrug resistance in Gram-negative bacteria. Curr Opin Microbiol. 2001. 4: 
p. 500-508. 
98. Eswaran J, Koronakis E, Higgins MK, Hughes C, Koronakis V. Three's company: 
component structures bring a closer view of tripartite drug efflux pumps. Curr Opin Struct 




99. Bartkus JM, Juni BA, Ehresmann K, Miller CA, Sanden GN, Cassiday PK, Saubolle M, 
Lee B, Long J, Harrison AR, Jr., Besser JM. Identification of a mutation associated with 
erythromycin resistance in Bordetella pertussis: implications for surveillance of 
antimicrobial resistance. J Clin Microbiol. 2003. 41: p. 1167-1172. 
100. Weisblum B. Erythromycin resistance by ribosome modification. Antimicrob Agents 
Chemother. 1995. 39: p. 577-585. 
101. Olsen I, Dewhirst FE, Paster BJ, Busse H-J. Family I. Pasteurellaceae in Bergey's 
manual of systematic bacteriology, the Proteobacteria, part B the Gammaproteobacteria, 
Garrity GM, Brenner DJ, Krieg NR, Staley JT, Editors. 2005, Springer Verlag: New York. 
p. 851-912. 
102. Carter GR. Studies on Pasteurella multocida. I. A hemagglutination test for the 
identification of serological types. Am J Vet Res. 1955. 16: p. 481-484. 
103. Wilson BA, Ho M. Pasteurella multocida: from zoonosis to cellular microbiology. Clin 
Microbiol Rev. 2013. 26: p. 631-655. 
104. Carter GR. Improved hemagglutination test for identifying type A strains of Pasteurella 
multocida. Appl Microbiol. 1972. 24: p. 162-163. 
105. DeAngelis PL, Gunay NS, Toida T, Mao WJ, Linhardt RJ. Identification of the capsular 
polysaccharides of type D and F Pasteurella multocida as unmodified heparin and 
chondroitin, respectively. Carbohydr Res. 2002. 337: p. 1547-1552. 
106. Rimler RB. Presumptive identification of Pasteurella multocida serogroups A, D and F by 
capsule depolymerisation with mucopolysaccharidases. Vet Rec. 1994. 134: p. 191-192. 
107. Rimler RB, Rhoades KR. Serogroup F, a new capsule serogroup of Pasteurella 
multocida. J Clin Microbiol. 1987. 25: p. 615-618. 
108. Zbinden R. Gram negative bacteria: Aggregatibacter, Capnocytophaga, Eikenella, 
Kingella, Pasteurella, and other fastidious or rarley encountered Gram-negative rods in 
Manual of clinical microbiology, Jorgensen JH, Pfaller MA, Carroll KC, Funke G, Landry 
ML, Richter SS, Warnock DW, Editors. 2015, ASM: Washington DC. p. 652-666. 
109. Rhodes MB, New CW, Jr., Baker PK, Hogg A, Underdahl NR. Bordetella bronchiseptica 
and toxigenic type D Pasteurella multocida as agents of severe atrophic rhinitis of swine. 
Vet Microbiol. 1987. 13: p. 179-187. 
110. Galdiero M, Pisciotta MG, Marinelli A, Petrillo G, Galdiero E. Coinfection with BHV-1 
modulates cell adhesion and invasion by P. multocida and Mannheimia (Pasteurella) 
haemolytica. New Microbiol. 2002. 25: p. 427-436. 
111. Boyce JD, Chung JY, Adler B. Pasteurella multocida capsule: composition, function and 
genetics. J Biotechnol. 2000. 83: p. 153-160. 
112. Glorioso JC, Jones GW, Rush HG, Pentler LJ, Darif CA, Coward JE. Adhesion of type A 
Pasteurella mulocida to rabbit pharyngeal cells and its possible role in rabbit respiratory 
tract infections. Infect Immun. 1982. 35: p. 1103-1109. 
113. Doughty SW, Ruffolo CG, Adler B. The type 4 fimbrial subunit gene of Pasteurella 




114. Petersen SK, Foged NT. Cloning and expression of the Pasteurella multocida toxin gene, 
toxA, in Escherichia coli. Infect Immun. 1989. 57: p. 3907-3913. 
115. Wilson BA, Ho M. Pasteurella multocida toxin interaction with host cells: entry and 
cellular effects. Curr Top Microbiol Immunol. 2012. 361: p. 93-111. 
116. Weber DJ, Wolfson JS, Swartz MN, Hooper DC. Pasteurella multocida infections. Report 
of 34 cases and review of the literature. Medicine. 1984. 63: p. 133-154. 
117. Ganiere JP, Escande F, Andre G, Larrat M. Characterization of Pasteurella from gingival 
scrapings of dogs and cats. Comp Immunol Microbiol Infect Dis. 1993. 16: p. 77-85. 
118. Schwarz S. Mechanisms of antimicrobial resistance in Pasteurellaceae in 
Pasteurellaceae: biology, genomics and molecular aspects, Kuhnert P, Christensen H, 
Editors. 2008, Caister Academic Press: Norfolk, UK. p. 199-228. 
119. Rosenau A, Labigne A, Escande F, Courcoux P, Philippon A. Plasmid-mediated ROB-1 
β-lactamase in Pasteurella multocida from a human specimen. Antimicrob Agents 
Chemother. 1991. 35: p. 2419-2422. 
120. Kehrenberg C, Schwarz S. dfrA20, a novel trimethoprim resistance gene from 
Pasteurella multocida. Antimicrob Agents Chemother. 2005. 49: p. 414-417. 
121. Livrelli V, Peduzzi J, Joly B. Sequence and molecular characterization of the ROB-1 β-
lactamase gene from Pasteurella haemolytica. Antimicrob Agents Chemother. 1991. 35: 
p. 242-251. 
122. Kehrenberg C, Schwarz S. Identification of a truncated, but functionally active tet(H) 
tetracycline resistance gene in Pasteurella aerogenes and Pasteurella multocida. FEMS 
Microbiol Lett. 2000. 188: p. 191-195. 
123. Livrelli VO, Darfeuille-Richaud A, Rich CD, Joly BH, Martel JL. Genetic determinant of 
the ROB-1 β-lactamase in bovine and porcine Pasteurella strains. Antimicrob Agents 
Chemother. 1988. 32: p. 1282-1284. 
124. Naas T, Benaoudia F, Lebrun L, Nordmann P. Molecular identification of TEM-1 β-
lactamase in a Pasteurella multocida isolate of human origin. Eur J Clin Microbiol Infect 
Dis. 2001. 20: p. 210-213. 
125. Wu JR, Shieh HK, Shien JH, Gong SR, Chang PC. Molecular characterization of 
plasmids with antimicrobial resistant genes in avian isolates of Pasteurella multocida. 
Avian Dis. 2003. 47: p. 1384-1392. 
126. Kadlec K, Watts JL, Schwarz S, Sweeney MT. Plasmid-located extended-spectrum β-
lactamase gene blaROB-2 in Mannheimia haemolytica. J Antimicrob Chemother. 2019. 74: 
p. 851-853. 
127. Hansen LM, Blanchard PC, Hirsh DC. Distribution of tet(H) among Pasteurella isolates 
from the United States and Canada. Antimicrob Agents Chemother. 1996. 40: p. 1558-
1560. 
128. Hansen LM, McMurry LM, Levy SB, Hirsh DC. A new tetracycline resistance determinant, 
Tet H, from Pasteurella multocida specifying active efflux of tetracycline. Antimicrob 




129. Michael GB, Kadlec K, Sweeney MT, Brzuszkiewicz E, Liesegang H, Daniel R, Murray 
RW, Watts JL, Schwarz S. ICEPmu1, an integrative conjugative element (ICE) of 
Pasteurella multocida: analysis of the regions that comprise 12 antimicrobial resistance 
genes. J Antimicrob Chemother. 2012. 67: p. 84-90. 
130. Kehrenberg C, Salmon SA, Watts JL, Schwarz S. Tetracycline resistance genes in 
isolates of Pasteurella multocida, Mannheimia haemolytica, Mannheimia glucosida and 
Mannheimia varigena from bovine and swine respiratory disease: intergeneric spread of 
the tet(H) plasmid pMHT1. J Antimicrob Chemother. 2001. 48: p. 631-640. 
131. Kehrenberg C, Catry B, Haesebrouck F, de Kruif A, Schwarz S. tet(L)-mediated 
tetracycline resistance in bovine Mannheimia and Pasteurella isolates. J Antimicrob 
Chemother. 2005. 56: p. 403-406. 
132. Chaslus-Dancla E, Lesage-Descauses MC, Leroy-Sétrin S, Martel JL, Lafont JP. 
Tetracycline resistance determinants, Tet B and Tet M, detected in Pasteurella 
haemolytica and Pasteurella multocida from bovine herds. J Antimicrob Chemother. 
1995. 36: p. 815-819. 
133. Kehrenberg C, Schwarz S. Plasmid-borne florfenicol resistance in Pasteurella multocida. 
J Antimicrob Chemother. 2005. 55: p. 773-775. 
134. Vassort-Bruneau C, Lesage-Descauses MC, Martel JL, Lafont JP, Chaslus-Dancla E. 
CAT III chloramphenicol resistance in Pasteurella haemolytica and Pasteurella multocida 
isolated from calves. J Antimicrob Chemother. 1996. 38: p. 205-213. 
135. Michael GB, Bossé JT, Schwarz S. Antimicrobial resistance in Pasteurellaceae of 
veterinary origin. Microbiol Spectr. 2018. 6: p. 1-33. 
136. Kehrenberg C, Catry B, Haesebrouck F, de Kruif A, Schwarz S. Novel 
spectinomycin/streptomycin resistance gene, aadA14, from Pasteurella multocida. 
Antimicrob Agents Chemother. 2005. 49: p. 3046-3049. 
137. Wang Z, Kong LC, Jia BY, Liu SM, Jiang XY, Ma HX. Aminoglycoside susceptibility of 
Pasteurella multocida isolates from bovine respiratory infections in China and mutations 
in ribosomal protein S5 associated with high-level induced spectinomycin resistance. J 
Vet Med Sci. 2017. 79: p. 1678-1681. 
138. van Hoek AHAM, Mevius D, Guerra B, Mullany P, Roberts AP, Aarts HJM. Acquired 
antibiotic resistance genes: an overview. Front Microbiol. 2011. 2: p. 1-27. 
139. Kehrenberg C, Schwarz S. Occurrence and linkage of genes coding for resistance to 
sulfonamides, streptomycin and chloramphenicol in bacteria of the genera Pasteurella 
and Mannheimia. FEMS Microbiol Lett. 2001. 205: p. 283-290. 
140. Niemann L, Feudi C, Eichhorn I, Hanke D, Müller P, Brauns J, Nathaus R, Schäkel F, 
Hoeltig D, Wendt M, Kadlec K, Schwarz S. Plasmid-located dfrA14 gene in Pasteurella 
multocida isolates from three different pig-producing farms in Germany. Vet Microbiol. 
2019. 230: p. 235-240. 
141. Kehrenberg C, Tham NTT, Schwarz S. New plasmid-borne antibiotic resistance gene 
cluster in Pasteurella multocida. Antimicrob Agents Chemother. 2003. 47: p. 2978-2980. 
142. Slonczewski JL, Foster JW. Genome und Chromosomen in Mikrobiologie - Eine 
Wissenschaft mit Zukunft, Slonczewski JL, Foster JW, Editors. 2012, Springer Spektrum: 




143. Slonczewski JL, Foster JW. Gentransfer, Mutationen und Evolution des Genoms in 
Mikrobiologie - Eine Wissenschaft mit Zukunft, Slonczewski JL, Foster JW, Editors. 
2012, Springer Spektrum: Berlin, Heidelberg. p. 349-394. 
144. Slonczewski JL, Foster JW. Struktur und Funktion von Viren in Mikrobiologie - Eine 
Wissenschaft mit Zukunft, Slonczewski JL, Foster JW, Editors. 2012, Springer Spektrum: 
Berlin, Heidelberg. p. 255-297. 
145. Grinsted J, Bennet PM. Introduction in Plasmid technology, Grinsted J, Bennet PM, 
Editors. 1988, Academic press: San Diego, California. p. 1-10. 
146. Frost LS, Leplae R, Summers AO, Toussaint A. Mobile genetic elements: the agents of 
open source evolution. Nat Rev Microbiol. 2005. 3: p. 722-732. 
147. Shintani M, Sanchez ZK, Kimbara K. Genomics of microbial plasmids: classification and 
identification based on replication and transfer systems and host taxonomy. Front 
Microbiol. 2015. 6: p. 1-16. 
148. Lawley T, Wilkins BM, Frost LS. Bacterial conjugation in Gram-negative bacteria in 
Plasmid biology, Funnell BE, Phillips GJ, Editors. 2004, ASM Press: Washington. p. 203-
226. 
149. Francia MV, Varsaki A, Garcillan-Barcia MP, Latorre A, Drainas C, de la Cruz F. A 
classification scheme for mobilization regions of bacterial plasmids. FEMS Microbiol Rev. 
2004. 28: p. 79-100. 
150. Brisebois LM, Charlebois R, Higgins R, Nadeau M. Prevalence of Streptococcus suis in 
four to eight week old clinically healthy piglets. Can J Vet Res. 1990. 54: p. 174-177. 
151. MacInnes JI, Gottschalk M, Lone AG, Metcalf DS, Ojha S, Rosendal T, Watson SB, 
Friendship RM. Prevalence of Actinobacillus pleuropneumoniae, Actinobacillus suis, 
Haemophilus parasuis, Pasteurella multocida, and Streptococcus suis in representative 
Ontario swine herds. Can J Vet Res. 2008. 72: p. 242-248. 
152. Zhao Z, Wang C, Xue Y, Tang X, Wu B, Cheng X, He Q, Chen H. The occurrence of 
Bordetella bronchiseptica in pigs with clinical respiratory disease. Vet J. 2011. 188: p. 
337-340. 
153. Höltig D, Hennig-Pauka I, Beyerbach M, Thies K, Rehm T, Gerlach GF, Waldmann KH. 
Comparison of the diagnostic significance of clinical, radiographic and ultrasonographic 
results after an experimental aerosol infection of pigs with Actinobacillus 
pleuropneumoniae. Berl Münch Tierarztl Wochenschr. 2008. 121: p. 422-431. 
154. Shaaly A, Tellevik MG, Langeland N, Hoiby EA, Jureen R. Comparison of serotyping, 
pulsed field gel electrophoresis and amplified fragment length polymorphism for typing 
of Streptococcus pneumoniae. J Med Microbiol. 2005. 54: p. 467-472. 
155. van Belkum A, Tassios PT, Dijkshoorn L, Haeggman S, Cookson B, Fry NK, Fussing V, 
Green J, Feil E, Gerner-Smidt P, Brisse S, Struelens M. Guidelines for the validation and 
application of typing methods for use in bacterial epidemiology. Clin Microbiol Infect. 
2007. 13 Suppl 3: p. 1-46. 
156. Vela AI, Goyache J, Tarradas C, Luque I, Mateos A, Moreno MA, Borge C, Perea JA, 
Dominguez L, Fernandez-Garayzabal JF. Analysis of genetic diversity of Streptococcus 
suis clinical isolates from pigs in Spain by pulsed-field gel electrophoresis. J Clin 




157. Cloutier G, D'Allaire S, Martinez G, Surprenant C, Lacouture S, Gottschalk M. 
Epidemiology of Streptococcus suis serotype 5 infection in a pig herd with and without 
clinical disease. Vet Microbiol. 2003. 97: p. 135-151. 
158. Silva LMG, Baums CG, Rehm T, Wisselink HJ, Goethe R, Valentin-Weigand P. 
Virulence-associated gene profiling of Streptococcus suis isolates by PCR. Vet Microbiol. 
2006. 115: p. 117-127. 
159. Allgaier A, Goethe R, Wisselink HJ, Smith HE, Valentin-Weigand P. Relatedness of 
Streptococcus suis isolates of various serotypes and clinical backgrounds as evaluated 
by macrorestriction analysis and expression of potential virulence traits. J Clin Microbiol. 
2001. 39: p. 445-453. 
160. Berthelot-Hérault F, Marois C, Gottschalk M, Kobisch M. Genetic diversity of 
Streptococcus suis strains isolated from pigs and humans as revealed by pulsed-field 
gel electrophoresis. J Clin Microbiol. 2002. 40: p. 615-619. 
161. Blume V, Luque I, Vela AI, Borge C, Maldonado A, Dominguez L, Tarradas C, 
Fernandez-Garayzabal JF. Genetic and virulence-phenotype characterization of 
serotypes 2 and 9 of Streptococcus suis swine isolates. Int Microbiol. 2009. 12: p. 161-
166. 
162. Engblom L, Lundeheim N, Strandberg E, Schneider Mdel P, Dalin AM, Andersson K. 
Factors affecting length of productive life in Swedish commercial sows. J Anim Sci. 2008. 
86: p. 432-441. 
163. Binns SH, Speakman AJ, Dawson S, Bennett M, Gaskell RM, Hart CA. The use of 
pulsed-field gel electrophoresis to examine the epidemiology of Bordetella 
bronchiseptica isolated from cats and other species. Epidemiol Infect. 1998. 120: p. 201-
208. 
164. Shin EK, Seo YS, Han JH, Hahn TW. Diversity of swine Bordetella bronchiseptica 
isolates evaluated by RAPD analysis and PFGE. J Vet Sci. 2007. 8: p. 65-73. 
165. Khattak MN, Matthews RC. Genetic relatedness of Bordetella species as determined by 
macrorestriction digests resolved by pulsed-field gel electrophoresis. Int J Syst Evol 
Microbiol. 1993. 43: p. 659-664. 
166. Marois C, Fablet C, Gaillot O, Morvan H, Madec F, Kobisch M. Molecular diversity of 
porcine and human isolates of Pasteurella multocida. J Appl Microbiol. 2009. 107: p. 
1830-1836. 
167. Pors SE, Hansen MS, Christensen H, Jensen HE, Petersen A, Bisgaard M. Genetic 
diversity and associated pathology of Pasteurella multocida isolated from porcine 
pneumonia. Vet Microbiol. 2011. 150: p. 354-361. 
168. Lainson FA, Aitchison KD, Donachie W, Thomson JR. Typing of Pasteurella multocida 
isolated from pigs with and without porcine dermatitis and nephropathy syndrome. J Clin 
Microbiol. 2002. 40: p. 588-593. 
169. Gunawardana GA, Townsend KM, Frost AJ. Molecular characterisation of avian 
Pasteurella multocida isolates from Australia and Vietnam by REP-PCR and PFGE. Vet 
Microbiol. 2000. 72: p. 97-109. 
170. Gottschalk M, Turgeon P, Higgins R, Beaudoin M, Bourgault AM. Susceptibility of 




171. Priebe S, Schwarz S. In vitro activities of florfenicol against bovine and porcine 
respiratory tract pathogens. Antimicrob Agents Chemother. 2003. 47: p. 2703-2705. 
172. Kadlec K, Kehrenberg C, Wallmann J, Schwarz S. Antimicrobial susceptibility of 
Bordetella bronchiseptica isolates from porcine respiratory tract infections. Antimicrob 
Agents Chemother. 2004. 48: p. 4903-4906. 
173. Peng Z, Liang W, Wang F, Xu Z, Xie Z, Lian Z, Hua L, Zhou R, Chen H, Wu B. Genetic 
and phylogenetic characteristics of Pasteurella multocida isolates from different host 
species. Front Microbiol. 2018. 9: p. 1408-1408. 
174. Ojo KK, Kehrenberg C, Schwarz S, Odelola HA. Identification of a complete dfrA14 gene 
cassette integrated at a secondary site in a resistance plasmid of uropathogenic 
Escherichia coli from Nigeria. Antimicrob Agents Chemother. 2002. 46: p. 2054-2055. 
175. Miranda A, Avila B, Diaz P, Rivas L, Bravo K, Astudillo J, Bueno C, Ulloa MT, Hermosilla 
G, Del Canto F, Salazar JC, Toro CS. Emergence of plasmid-borne dfrA14 trimethoprim 
resistance gene in Shigella sonnei. Front Cell Infect Microbiol. 2016. 6: p. 77. 
176. Bossé JT, Li Y, Walker S, Atherton T, Fernandez Crespo R, Williamson SM, Rogers J, 
Chaudhuri RR, Weinert LA, Oshota O, Holden MT, Maskell DJ, Tucker AW, Wren BW, 
Rycroft AN, Langford PR. Identification of dfrA14 in two distinct plasmids conferring 
trimethoprim resistance in Actinobacillus pleuropneumoniae. J Antimicrob Chemother. 





Table S1 Information of the prescribed antimicrobials on the different farms with their treatment success 
determined by a modified respiratory health score according to Höltig and colleagues (2008). The total 
score represents the herd fitness, identified by the median score of 15 and 10 examined pigs at time 
points B/D and C/E, respectively. The scores of pigs 1-3 indicate the health of the three BALF animals. 
A score of ≤0.18 reflects healthy and ≥0.18 respiratory diseased animals. The pathogens 
B.  bronchiseptica, S. suis and P. multocida represent the number of colonies isolated from the BALFs. 









Score    
Pig 1
Score    
Pig 2
Score    
Pig 3
B. bronchiseptica S. suis P. multocida
1 B AMX 0.89 1 1 0.33 8 8  - 
1 C 0.42 0.33 0.5 0.33 3  - 1
2 B AUG 0.72 0.72 1.39 0.5 4 12 8
2 C 0.33 0.17 0.17 0.5 8 3 4
3 B AMX 0.56 0.89 0.89 0.33  - 7 4
3 C 0.33 0.33 0.17 1.22 12 6 6
6 B DOX 1.78 1.78 1.78 1.78  - 12 8
6 C 0.42 1.17 0.5 0.33  - 12  - 
6 D DOX 1.89 1.89 1.72 1.72  - 8  - 
6 E 0.67 0.72 1.22 1.56  -  - 4
9 B DOX 1.22 1.39 1.22 1.39  - 5  - 
9 C 0.36 0.33 0.33 0.83  - 7  - 
11 B DOX 0.72 0.56 1.06 0.56  -  -  - 
11 C 0.5 1.45 0.39 0.5  -  -  - 
11 D AMX 0.56 0.56 0.72 0.56 8 8  - 
11 E 0.39 0.67 0.5 0.33 4 4  - 
12 B DOX 0.72 0.22 0.56 1.22  - 8  - 
12 C 0.33 0.33 0 0.17  - 4  - 
12 D DOX 1.06 0.89 1.39 0.89  - 8 4
12 E 0.72 0.72 0.72 0.72  - 4 1
13 B AMX 0.56 1.22 0.67 0.56  - 12 10
13 C 0.67 1.39 0.83 0.67 2 5 2
14 B DOX 0.72 0.39 0.89 0.72  - 12  - 
14 C 0.72 0 0.72 n.d.b  - 7  - 
18 B DOX 0.72 0.56 1.06 0.56  - 8  - 
18 C 0.39 0.39 0.56 0.17  - 7  - 
18 D DOX 0.89 1.11 0.89 0.72  - 11  - 
18 E 0.92 0.56 0.56 0.39  - 8  - 
19 B AMX 0.56 0.72 1.06 0.39 8 4 2
19 C 0.53 0.89 0.5 0.95  - 11  - 
20 B AMX 1.06 0.89 1.06 0.89 12 7 8
20 C 0.5 0.17 0.33 0.5 12  - 4
21 B TIA/FFN 0.89 1.06 0.89 0.89 3 10  - 
21 C 0.53 0.67 1.56 0.83 8 11  - 
22 B DOX 0.56 0.56 0.72 0.72  - 4  - 
22 C 0.33 0.17 0.33 0.5  - 7  - 
24 B DOX 1.06 1.28 1.06 0.89 8 8 5
24 C 0.75 1.22 0.83 1.22 12 4 4
25 B DOX 0.89 1.06 0.89 0.72 12 8  - 
25 C 0.75 0.89 0.56 0.67  - 7  - 
26 B DOX 0.72 1.22 0.72 1.06 4 12 4
26 C 0.36 0.89 0.39 0.33 4 8 4
27 B DOX 0.89 1.22 1.89 0.72  - 10 9
27 C 0.56 1.39 1 0.33  - 12 4
29 B AMX 0.89 1.45 1.39 1.06  - 1  - 
29 C 0.25 0.17 0.33 0.17  -  -  - 
30 B AMX 0.56 0.56 0.72 0.89  - 4 1
30 C 0.33 0.33 0.17 0.33  - 4 1
a AMX amoxicillin; AUG amoxicillin/clavulanic acid; DOX doxycycline; TIA/FFN tiamulin/florfenicol 





Figure S1 S. suis PFGE patterns of Farms 14, 29 and 30 obtained from several sampling time points 
with indistinguishable PFGE profiles per farm. S. suis was digested with SmaI as described in 
Publication I and PFGE analysis was performed with BioNumerics v7.5 (bioMérieux, Applied Math, 
Sint-Martens-Latem, Belgium) by a cluster analysis with a tolerance of 1 % and optimization of 0.5 %. 
The dendrogram indicates the similarity of the analysed isolates. 
 
Figure S2 S. suis PFGE patterns of Farm 2 with closely related isolates at several time points indicated 






Figure S3 S. suis PFGE patterns of Farms 2, 3, 14, 25, 20 and 30, each with indistinguishable profiles 
between two farms. Digestion experiment and PFGE analysis was performed as described in Figure S1. 
 
Figure S4 B. bronchiseptica PFGE patterns of different farms showed in parts closely related profiles. 
B. bronchiseptica was digested with XbaI as described in Publication I and PFGE analysis was 
performed as explained in Figure S1. 
 
Figure S5 P. multocida PFGE patterns of Farms 5 and 7 obtained at the same sampling time point A. 
Macrorestriction revealed different patterns within a farm at the same time. Information about the 
serotype is provided behind the farm numbers. P. multocida was digested with SmaI as described in 





Figure S6 P. multocida PFGE patterns of different farms with in parts closely related isolates between 
the farms. Information about the serotype is provided behind the farm numbers. P. multocida was 
digested with SmaI as described in Publication I and PFGE analysis was performed as clarified in 
Figure S1.
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